We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

185,000

200M

Our authors are among the

154
Countries delivered to

TOP 1%

12.2%

most cited scientists

Contributors from top 500 universities



WEB OF SCIENCE

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



Bacterial Genetics of Large Mammalian DNA Viruses: Bacterial Artificial Chromosomes as a Prerequisite for Efficiently Studying Viral DNA Replication and Functions

Felix Wussow^{1,2}, Tanja Spieckermann¹, Anne Brunnemann¹, Linda Hüske¹, Tuna Toptan^{1,3} and Helmut Fickenscher¹

¹Institute for Infection Medicine, Christian Albrecht University of Kiel and

University Medical Center Schleswig-Holstein, Kiel,

²City of Hope Comprehensive Cancer Center and Beckman Research Institute,

Translational Vaccine Research, Duarte, California,

³Cancer Virology Program, University of Pittsburgh Cancer Institute,

Pittsburgh, Pennsylvania,

¹Germany

^{2,3}USA

1. Introduction

Large DNA viruses such as herpesviruses and poxviruses constitute a group of highly relevant pathogens for animals and humans. Genetic and functional analysis of these viruses has been a constant research challenge mainly because of their large and complex genomes, which are difficult to access by standard molecular biology techniques. Homologous recombination is the major principle for the manipulation of such viral genomes. The simple site-directed integration of a selection marker gene into the viral DNA allowed for the first time the enrichment of recombinants in permissive eukaryotic cells (Mocarski et al., 1980; Smiley, 1980). Essential genomic sites including those involved in DNA replication cannot be efficiently investigated by this method, since mutants with such defects would not start to replicate and, thus, would not be generated. To some extent, amplicon constructs in the presence of a wild-type helper virus have been instrumental for functional studies, which were, however, hampered by the background of similar helper virus sequences. Such limitations were resolved by cloning entire virus genomes as cosmid libraries in Escherichia (E.) coli (van Zijl et al., 1988). The virus is reconstituted in permissive mammalian cells after cotransfection of overlapping viral cosmids. Essential genome sites involved in DNA replication can then eventually be identified by providing the missing function through trans-complementation. However, unwanted second-site mutations after recombination of the homologous overlapping sequences and the resulting spontaneous mutation possibilities at the overlapping stretches are considerable disadvantages, rendering this procedure rather unreliable.

The major methodological break-through was achieved by cloning entire herpesvirus genomes as infectious large plasmids, co-called bacterial artificial chromosomes (BACs) in E. coli (Messerle et al., 1997). This technology was first introduced for the murine cytomegalovirus genome and was subsequently applied to numerous other virus pathogens. This permitted the stable maintenance and the targeted mutagenesis of the virus genomes as single plasmids in E. coli. Afterwards, the transfer of the BAC DNA into viruspermissive eukaryotic cells allowed the reconstitution of the mutant virus representing a homogenous population. Initially, the selection marker and the BAC cassette remained obligatory after the manipulation of the genomes in E. coli and the virus reconstitution in eukaryotic cells, respectively. As an improvement, site-specific recombinase systems were applied for the excision of the BAC vector sequences, leaving behind only one recombinase recognition site. Also transposon mutagenesis was used for generating libraries of virus genomes saturated with single-site mutations. As the second break-through, manipulation techniques such as en passant mutagenesis enabled the seamless alteration of the BAC DNA in bacteria and, thus, the reconstitution of mutant progeny virus which was free of secondary mutations such as selection markers or recombinase recognition sites (Tischer et al., 2006). The third break-through was achieved, when all BAC vector sequences were deleted autonomically after transfection of restructured BACs into permissive eukaryotic cells, allowing the generation of virus progeny completely devoid of any operational sequences. This approach uses functional features of virus DNA replication in order to reconstitute the wild-type configuration at the previous BAC vector insertion site. In addition, methods were developed for the targeted transposition of the vector sequence within a BAC construct in order to optimize genomic vector design. Thus, BAC constructs of large mammalian DNA viruses have become crucial for functional studies, even of essential genes including that for viral DNA replication.

In this review, we summarize the development of viral BAC vectors and the bacterial genetics tools used. We discuss the advantages and disadvantages of different BAC vector strategies for herpes- and poxviruses, as well as the application potential for functional studies into DNA replication and other viral functions and the perspectives for future preventive and therapeutic strategies.

2. Generation of recombinant large DNA viruses

Herpesvirus genomes consist of 120-250 kb double-stranded (ds) linear DNA which is circularized after infection of the cell. They are composed of different unique and repetitive regions with densely packed or even overlapping open reading frames of approximately 70-220 genes. Poxvirus genomes are even larger. Whereas poxviruses replicate in the cytoplasm, the DNA replication of herpesviruses occurs in the nucleus. Functional studies in large DNA viruses require the precise generation of virus mutants; thus, accessory operational sequences and selection markers should be avoided in order to exclude unwanted side-effects which may hide or distort the effects mediated by the precise mutant position. The development of precise mutagenesis protocols has been a constant challenge in herpes- and poxvirology. Eight human herpesviruses are of major interest in this research field: herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus (EBV), human cytomegalovirus (hCMV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7), and Kaposi's sarcoma-associated herpesvirus (KSHV). In addition, a series of animal herpesviruses have been subjected to recombinant mutagenesis. While all these herpesviruses are capable of persisting life-long in the human

body, they can be reactivated and cause disease under specific conditions during primary infection or during reactivation. Among the poxviruses, the major interest lies in vaccinia viruses which are highly important tools for vaccine development.

2.1 Basic strategies for the manipulation of large viral genomes

The classical, pre-recombinant strategy for mutant generation was developed approximately forty years ago by the targeted phenotypic selection of chemically induced and randomly generated temperature-sensitive variants which are conditionally expressing specific virus proteins (Schaffer, 1975). This strategy was a pacemaker for virus research and allowed the temperature-dependent study of defined virus functions, including properties which are essential for virus replication. However, the precise definition of the respective mutation was demanding and unwanted second-site mutations were difficult to exclude.

The size of herpes- and poxviral genomes was by far too large in order to utilize naturally occurring unique endonuclease recognition sites for the precise manipulation of the viral DNA. The targeted mutagenesis of herpes- or poxviral genomes was successfully achieved by the integration of a selection marker flanked by viral DNA sequences including the desired genetic mutation by homologous recombination into the virus genome during virus replication in cultured permissive eukaryotic cells (Manning & Mocarski, 1988; Mocarski et al., 1980; Post & Roizman, 1981; Smiley, 1980; Spaete & Mocarski, 1987). Since the homologous recombination occurred as a rare event, the recombinants were difficult to isolate from a dominating amount of wild-type virus. This method did not yet allow the targeting of essential genes, since the strategy was dependent on active virus replication.

A considerable step forward was done by introducing the concept of virus reconstitution by cotransfection of overlapping genomic cosmid clones into permissive cells (Cohen & Seidel, 1993; Cunningham & Davison, 1993; Kemble et al., 1996; Tomkinson et al., 1993; van Zijl et al., 1988). For this purpose, virion DNA was prepared, degraded to fragment sizes of approximately 30-40 kb, and cloned in E. coli into cosmid vector libraries. Selected overlapping and complementing genomic cosmid DNA clones were then selected and transfected as sets of three to five cosmids into permissive cells in order to reconstitute infectious virus. The major advantage of the cosmid complementation method is the fact, that the cloned viral DNA can be manipulated precisely by molecular biology or bacterial genetic techniques. Moreover, the obtained virus progeny is free of cosmid vector sequences, although selection markers cannot be avoided in most cases. By providing essential functions in trans or by trans-complementing cell lines, even essential virus genes were analyzed using this method. The cosmid-complementation technique is limited in eukaryotic cells by illegitimate events of homologous recombination or unwanted secondsite mutations which are difficult to exclude. The technique of cosmid complementation was instrumental for developing entire virus genomes in the form of viral BACs.

2.2 Bacterial artificial chromosomes of entire large viral genomes

BACs were established for studies in human and animal genetics. BACs are single-copy bacterial F-factor-derived plasmids of approximately 7.5 kb which carry an own origin of replication, encode own DNA replication factors (*e.g.*, repE), and an antibiotic resistance function (*e.g.*, against chloramphenicol). BACs can stably maintain DNA molecules of up to 300 kb in recombination-deficient *E. coli* strains (Shizuya et al., 1992). A frequently used BAC vector is pBeloBAC11. The F-plasmid based vector sequences are often designated "mini-F"

fragments. The BAC copy number is strictly restricted to one or two copies per bacterial cell by regulatory elements (e.g., parA & parB) of the mini-F vector. Thus, intermolecular homologous recombination events are largely excluded. However, repeated or duplicated sequences can still undergo homologous recombination (Shizuya et al., 1992). Bacteriophage P1-based vectors (PACs) are comparable to BACs. In contrast to BACs, yeast artificial chromosomes (YACs) can accommodate even larger inserts. However, YACs often have chimeric structures and sequence rearrangements (Ramsay, 1994; Schalkwyk et al., 1995). BACs show higher insert stability in *E. coli* in comparison to cosmid-based plasmids, which are restricted to DNA-fragment sizes of up to 50 kb (Kim et al., 1992). Therefore, BACs have become the vectors of choice for the cloning of large and complex genomes in E. coli (Ioannou et al., 1994; Shizuya et al., 1992). Moreover, BACs are instrumental in sequencing strategies, for functional genomics, and for the construction of gene targeting or gene therapy vectors (Copeland et al., 2001; Sparwasser & Eberl, 2007; Yang & Gong, 2005). For the application in cloning large DNA virus genomes, the BAC vector needs flanking virus homology regions of 300-500 bp for the precise targeting into the desired genomic region. Depending on the planned applications, accessory operational markers are included, such as genes for an autofluorescent protein, luciferase, or antibiotic resistance. Many strategies include flanking recognition sites (e.g., loxP) for recombinases (e.g., Cre) at the ends of the BAC insert sequence in order to allow the vector excision from recombinant progeny viruses.

Herpes- and also poxvirus BACs (Figure 1) can be constructed by inserting a mini-F vector into a specific site of a non-essential genomic region via homologous recombination of a linearized recombination construct during active virus replication in permissive eukaryotic cells after lipofection or electroporation. The recombination fragment may be cotransfected with virion DNA or the transfected culture may superinfected with wild-type virus after transfection. The transfer of the circular replication intermediates of recombinant progeny viruses or artificially created circular DNA is carried out into a RecA- E. coli strain, such as DH10B (Messerle et al., 1997). Alternatively, the BAC vector can be inserted into a nonessential region of a specific viral cosmid clone, in addition to the pre-existing cosmid vector fragment. After cotransfection of sets of three to five overlapping viral cosmids into permissive cells, the BAC vector-containing virus is reconstituted. Similarly, the circular replication intermediates are then transferred into E. coli (Saeki et al., 1998; Tischer et al., 2007). A detailed molecular analysis of the viral BACs is necessary in order to show genetic integrity. Importantly, viral BAC DNA can be prepared in large quantity and high quality in order to compensate for the inefficient transfection procedures into permissive eukaryotic cells. After retransfer of the viral BAC into permissive cells, the resulting recombinant virus is reconstituted and compared with wild-type virus for genome structure and replication properties. If possible, plaque purification is recommended in order to ensure a homogenous virus population. Selectable markers such as genes for autofluorescent proteins may be useful for the rapid identification of recombinant viruses. A detailed analysis is necessary since unwanted genotypic and phenotypic changes in viral BACs have been observed (Ali et al., 2009; Messerle et al., 1997). In viruses with particular large genomes, such as cytomegaloviruses, the 7.5 kb BAC vector insert may already lead to obvious retardation of viral replication (Yu et al., 2002).

After the initial cloning of murine cytomegalovirus (mCMV; Messerle et al., 1997), the genomes of many herpesviruses, some poxviruses, and some large RNA viruses were constructed as infectious viral BACs (Table 1; Adler et al., 2003; Britt, 2000; Brune et al., 1999,




Fig. 1. Generation and mutagenesis of herpesvirus BACs. A) Cloning of a herpesviral genome as a bacterial artificial chromosome (BAC). A mini-F vector (green) is inserted into the viral DNA via homologous recombination (crossed lines) during virus replication in infected permissive eukaryotic cells. Circular replication intermediates are isolated and transferred into *E. coli* to establish an infectious viral BAC. Alternatively, the mini-F plasmid is first inserted into a viral cosmid (blue) DNA clone. Overlapping linear viral genome fragments from cosmid vectors are subsequently transfected into permissive cells. Circular DNA intermediates of recovered replicating virus are then isolated and transformed into *E. coli*. B) Herpesvirus BAC technology. The herpesviral BAC is maintained in *E. coli* and a mutation is introduced into the viral DNA by homologous recombination. The BAC is isolated and transfected into permissive eukaryotic cells, where mutant progeny is reconstituted (adapted from Felix Wussow, Ph.D. thesis, Christian Albrecht University of Kiel, 2009).

2000; Feederle et al., 2010; McGregor & Schleiss, 2001b; Wagner & Koszinowski, 2004; Wagner et al., 2002, 2004; Warden et al., 2011). Full-length viral DNA can be maintained and mutagenized in E. coli and delivered into permissive eukaryotic cells for virus reconstitution. Since poxviruses replicate in the cytoplasm, the initiation of viral transcription and DNA replication requires the presence of a related helper virus (Domi and Moss, 2002). Infectious homogenous progeny is recovered from mutated viral BAC-DNA in a defined manner without any further homologous recombination events to restore genome integrity, in contrast to virus reconstitution from overlapping cosmid fragments. Nevertheless, mini-F sequences in a non-essential genomic region can interfere with specific viral functions especially in further in vivo experiments. The complete removal of the mini-F vector by homologous recombination has been limited to laborious cotransfection experiments or to BAC constructs with restricted stability in bacteria (Strive et al., 2007; Wagner et al., 1999; Yu et al., 2002). Alternatively, the vector elements can be flanked by recognition sites for site-specific recombinases, which leave behind only one small recognition sequence (Adler et al., 2000, 2001; Chang & Barry, 2003; Smith & Enquist, 2000; Strive et al., 2006; Tanaka et al., 2003; Zhao et al., 2008).

a-Herpesviruses - Simplexviruses - Simplexviruses Herpes simplex virus type 1 human HSV-1 Horsburgh et al., 1999a, b; Nagel et al., 2003 Herpes simplex virus type 2 human HSV-2 Mescada et al., 2004 Varicella-zoster virus human VZV Nagaike et al., 2004; Tischer et al., 2007; Zhang et al., 2007 Simian varicella virus rhesus PrV Simita beresvirus type 1 bovine BHV-1 Mahony et al., 2002; Robinson et al., 2007; Zhang et al., 2007 Seuine herpesvirus type 1 equine EHV-1 Smith & Enquist, 1999 Brazeau et al., 2011 Gray et al., 2011 Canine herpesvirus type 1 equine EHV-1 Smith & Enquist, 1999 Budolph & Osterrieder, 2002; Rudolph et al., 2002 Canine herpesvirus type 1 equine EHV-1 Costes et al., 2006 Tai et al., 2010 Marek's disease virus turkey MDV Schumacher et al., 2006 Tai et al., 2010 Human cytomegalovirus turkey MDV Schumacher et al., 2000 Murphy et al., 2003; Sinzger et al., 2001; Murphy et al., 2003; Sinzger et al., 2001; Murphy et al., 2003; Sinzger et al., 2001 Murphy et al., 2003; Sinzger et al., 2008 <t< th=""><th>X7.</th><th><u> </u></th><th>A 1 1</th><th>W:</th></t<>	X7.	<u> </u>	A 1 1	W:
- Simplex virus type 1 human HSV-1 Horsburgh et al., 1999a, b; Nagel et al., 2008; Saeki et al., 1998; Stravropoulos & Strathdee, 1998; Tanaka et al., 2003 Meseda et al., 2003 Meseda et al., 2004 Tischer et al., 2007; Wussow et al., 2004; Tischer et al., 2007; Zhang et al., 2009; Yoshii et al., 2007; Zhang et al., 2008; Zhang et al., 2006; Zhang et al., 2008; Zhang et al., 2008; Zhang et al., 2008; Zhang et al., 2009; Zhang et al., 2009; Zhang et al., 2008; Zhang et al., 2009; Zhang et al., 2009; Zhang et al., 2009; Zhang et al., 2006; Zhang et al., 2008; Zhang et al., 2008; Zhang et al.	Virus	Species	Abbr.	Major references
Herpes simplex virus type 1 Herpes simplex virus type 2 - Varicelloviruses Varicella-zoster virus Varicella-zoster virus human HSV-2 Nagaike et al., 2004; Tischer et al., 2007; Wussow et al., 2008; Saekie et al., 2009; Hahn et al., 2002; All et al., 2008; Mussomer et al., 2008; Mussomer et al., 2008; Mussomer et al., 2009; Wissinger et al., 2009; Mussomer et al., 2008; Muss				
2008; Saeki et al., 1998; Stravropoulos & Strathce, 1998; Tanaka et al., 2003 Meseda et al., 2004 Herpes simplex virus type 2 Varicella-zoster virus human HSV-2 Nagaike et al., 2004; Tischer et al., 2007; Wussow et al., 2009; Yoshii et al., 2007; Zhang et al., 2008; Zhang et al., 2002; Robinson et al., 2008; Zhang et al., 2002; Rudolph et al., 2006; Tai et al., 2010; Zhirue et al., 2006; Tai et al., 2010; Zhirue et al., 2006; Tai et al., 2010; Zhirue et al., 2006; Tai et al., 2000; Zhirue et al., 2000; Zhir				
Strathcke, 1998; Tanaka et al., 2003	Herpes simplex virus type 1	human	HSV-1	O O
Herpes simplex virus type 2 - Varicella-zoster virus Varicella-zost				
- Varicelloviruses Varicella-zoster virus Varicella-zoster virus Nagaike et al., 2004; Tischer et al., 2007; Wussow et al., 2009; Yoshii et al., 2007; Zhang et al., 2007; Zhang et al., 2007; Zhang et al., 2011 Simian varicella virus PrV Smith & Enquist, 1999 Bovine herpesvirus type 1 bovine BHV-1 Rudolph & Osterrieder, 2002; Rudolph et al., 2002 Canine herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2007 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2007 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2008 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2008 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2008 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2008 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2008 Feline herpesvirus type 1 feline FHV-1 Tasmisisible gastroenteritis FHV-1 Tasmisisible gastroenteritis FHV-1 Tasmisisible gastroenteritis Fe		_		
Varicella-zoster virus human VZV Nagaike et al., 2004; Tischer et al., 2007; Wussow et al., 2009; Yoshii et al., 2007; Zhang et al., 2007 Simian varicella virus Pseudorabies virus Equine herpesvirus type 1 equine EHV-1 Radolph & Osterrieder, 2002; Rudolph et al., 2002 Rudolph & Osterrieder, 2002; Rudolph et al., 2000 Strive et al., 2006 Strive et al., 2006 Costes et al., 2006 Strive et al., 2006 Strive et al., 2006 Costes et al., 2006 Strive et al., 2006 Strive et al., 2007 Smith & Enquist, 1999 Rudolph & Osterrieder, 2002; Rudolph et al., 2002 Strive et al., 2006 Strive et al., 2006 Strive et al., 2006 Costes et al., 2006 Strive et al., 2007 Murshy et al., 2007 Murshy et al., 2007 MucGregor & Schleiss, 2001a HIV-6 Strive et al., 2009		human	HSV-2	Meseda et al., 2004
Wussow et al., 2009; Yoshii et al., 2007; Zhang et al., 2007; Zhang et al., 2007; Zhang et al., 2007			1 /	
Simian varicella virus Pseudorabies virus Privative Enquise EHV-1 Rudolph & Osterrieder, 2002; Rudolph et al., 2002 Canine herpesvirus type 1 Feline herpesvirus Phy-1 Costes et al., 2006 Feline herpesvirus Phy-1 Costes et al., 2006 Fai et al., 2007 Baigent et al., 2006 Pherpesviruses - Cytomegalovirus Phuman cytomegalovir	Varicella-zoster virus	human	VZV	
Simian varicella virusrhesus porcineSVV presudorabies virusBrazeau et al., 2011; Gray et al., 2011Pseudorabies virusporcinePrV prvSmith & Enquist, 1999Bovine herpesvirus type 1equineEHV-1Mahony et al., 2002; Robinson et al., 2008Equine herpesviruscanineCHV Strive et al., 2006Strive et al., 2006; Tai et al., 2010Feline herpesvirusturkeyMDV Schumacher et al., 2006Marek's disease virusturkeyHVTBaigent et al., 2006Turkey herpesvirusturkeyHVTBaigent et al., 2006P-Herpesviruses- QytomegalovirusesHuman cytomegalovirushumanhCMVBorst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008Rhesus cytomegalovirusrhesusrhCMVMesserle et al., 1997Murine cytomegalovirusguinea piggpCMVMcGregor & Schleiss, 2001aAnsoeloviruseshumanHHV-6Borenstein & Frenkel, 2009Herpesviruses- LymphocryptovirusesEpstein-Barr virushumanEBVDelecluse et al., 1998- Rhadinoviruseskaposi-Sarcoma associated herpesvirushumanKSHVDelecluse et al., 2001; Zhou et al., 2002Murine γ-herpesvirus 68humanKSHVDelecluse et al., 2000; Song et al., 2005Rhesus rhadinovirusrhesusRRVEstep et al., 2000Murine γ-herpesvirussaimirineMHV-68Adler et al., 2000; Song et al., 2005KHVCostes et al., 2008; Domi & Moss, 2002; Meissi				
Pseudorabies virus Bovine herpesvirus type 1 Bovine herpesvirus type 1 Equine herpesvirus type 1 Edine herpesvirus type 1 Edine herpesvirus type 1 Feline herpesvirus turkey therpesvirus turkey turkey therpesvirus turkey turkey therpesvirus to turkey turkey turkey tal., 2005 Feline herpesvirus turkey therpesvirus turkey turkey turkey tal., 2002 Feline herpesvirus turkey turkey tal., 2003 Feline herpesvirus turkey turkey tal., 2008 Feline herpesvirus turkey turke				, , , , , , , , , , , , , , , , , , , ,
Bovine herpesvirus type 1 Equine herpesvirus type 1 Canine herpesvirus type 1 Feline herpesviru		rhesus		
Equine herpesvirus type 1 equine EHV-1 Rudolph & Osterrieder, 2002; Rudolph et al., 2002 Canine herpesvirus type 1 feline FHV-1 Costes et al., 2006 Feline herpesvirus type 1 feline FHV-1 Costes et al., 2006; Tai et al., 2010 -Mardiviruses Marek's disease virus turkey MDV Schumacher et al., 2000 Turkey herpesvirus turkey HVT Baigent et al., 2006 β-Herpesviruses - Cytomegaloviruses Human cytomegalovirus human hCMV Borst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008 Rhesus cytomegalovirus murine mCMV Messerle et al., 1997 Guinea pig cytomegalovirus guinea pig gpCMV - Roseoloviruses - Lymphocryptoviruses - Lymphocryptoviruses - Lymphocryptoviruses - Rhadinoviruse - Rhadinoviruse - Rhadinoviruse - Rhadinoviruse - Rhadinoviruse - Rhadinovirus - Rhesus rhadinovirus - Rhodinoviruses - Rhadinoviruse - Rhadinoviruses - Rhadinoviruse - Rhadinoviruse - Rhadinovirus - Rhesus rhadinovirus - Resus rhadinovirus - Resus rhadinovirus - Resus rhadinovirus - Rurv - Strepesvirus (2007) - Murine γ-herpesvirus (8) - Human - HIV-6 - Borenstein & Frenkel, 2009 - Poelecluse et al., 2001; Zhou et al., 2002 - Resus et al., 2007 - Murine γ-herpesvirus (8) - Human - RRV - Step et al., 2007 - Wirthey rhadinovirus - Rurv - Strepesvirus rhadinovir		porcine		
Canine herpesvirus Canine CHV Strive et al., 2006		bovine		
Canine herpesviruscanine feline herpesvirus type 1 —MardivirusesCanine felineCHV FHV-1 FHV-1 Costes et al., 2006; Tai et al., 2010Marek's disease virus Turkey herpesvirus β-Herpesviruses - Cytomegaloviruses Human cytomegalovirusturkey turkeyMDV HVTSchumacher et al., 2000 Baigent et al., 2006Human cytomegaloviruses Human cytomegalovirushuman n hCMVBorst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008Rhesus cytomegalovirus Murine cytomegalovirus - Roseoloviruses - Human herpesvirus 6 - LymphocryptovirusesrhcMV murine guinea pig ypCMVMcGregor & Schleiss, 2001a- Rhadinoviruses - Lymphocryptoviruses - RhadinoviruseshumanHHV-6Borenstein & Frenkel, 2009Kaposi-Sarcoma associated herpesvirus - Rhadinovirus - Rhadinovi	Equine herpesvirus type 1	equine	EHV-1	
Feline herpesvirus type 1 - Mardiviruses Marek's disease virus Turkey herpesvirus turkey MDV Schumacher et al., 2000 Turkey herpesvirus turkey HVT Baigent et al., 2006 β-Herpesviruses - Cytomegaloviruses Human cytomegalovirus Rhesus cytomegalovirus Guinea pig cytomegalovirus Roseoloviruses Human herpesvirus 6 Human herpesvirus 6 - Lymphocryptoviruses - Lymphocryptoviruses Raposi-Sarcoma associated herpesvirus Rhesus rhadinovirus Rhesus RRV Resus RRV MDV Schumacher et al., 2000 Baigent et al., 2006 Borst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003, Sinzger et al., 2008 McGregor & Schleiss, 2001a Borenstein & Frenkel, 2009 P-Herpesviruses - Lymphocryptoviruses Epstein-Barr virus Aluman RSHV Delecluse et al., 1998 RRV Besus rhadinovirus RRV MHV-68 MHV-68 Herpesvirus saimiri RRV MHV-68 Herpesvirus saimiri Saimiriine HVS White et al., 2003; Toptan et al., 2001 Alloherpesvirus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Coronaviruses Transmissible gastroenteritis Porcine TGCV Almazan et al., 2000				
- Mardiviruses Marek's disease virus Turkey herpesvirus β-Herpesviruses - Cytomegalovirus Human cytomegalovirus Rhesus cytomegalovirus Murine cytomegalovirus Human herpesviruse - Roseoloviruses Human herpesviruse - Lymphocryptoviruses Epstein-Barr virus - Rhadinoviruse Rhesus rhadinovirus Rhesus rhadinovirus Rhesus human Human EBV Delecluse et al., 2001; Zhou et al., 2002 Posviruses Kaposi-Sarcoma associated Rherpesvirus 68 Human Herpesvirus 68 Human Herpesvirus Rhesus rhadinovirus Rhesus rhadinovirus Rhesus rhadinovirus Rhesus rhadinovirus Rhesus rhadinovirus Khesus rhadinovirus Rhesus rhadinovirus Rhesus rhadinovirus Khesus rhadinovirus Rhesus rhadinovirus Khesus rhadinovirus Resus rhadinovirus Rhesus rhadinovirus Khesus rhadinovirus Rhesus rhadinovirus Rhesus rhadinovirus Khesus rhadinovirus Rhesus rhadinovirus Khesus rhadinovirus Koi herpesvirus 88 Kaposi-Sarcoma associated Khu Costes et al., 2007 Khu Costes et al., 2008 Cottingham et al., 2008 Cottingham et al., 2008 Cottingham et al., 2008 Rhadinoviruses Transmissible gastroenteritis Figory Almazan et al., 2000		canine		
Marek's disease virus Turkey herpesvirusturkey turkeyMDV HVTSchumacher et al., 2006β-Herpesviruses - CytomegaloviruseshumanhCMVBorst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008Rhesus cytomegalovirus Murine cytomegalovirus - Roseoloviruses - Human herpesvirus 6 - Lymphocryptovirusesrhesus rhCMV chang & Barry, 2003 murine mCMV Messerle et al., 1997 guinea pig gpCMV McGregor & Schleiss, 2001a- Rhesus rytomegalovirus - Roseoloviruses - LymphocryptoviruseshumanHHV-6Borenstein & Frenkel, 2009γ-Herpesviruses - LymphocryptovirusesbumanEBVDelecluse et al., 1998Epstein-Barr virus - RhadinoviruseshumanEBVDelecluse et al., 2001; Zhou et al., 2002Kaposi-Sarcoma associated herpesvirushumanKSHVDelecluse et al., 2001; Zhou et al., 2002Murine γ-herpesvirus 68 Herpesvirus saimirRRV murine saimiriineEstep et al., 2007 MHV-68 Adler et al., 2000; Song et al., 2005 HerpesvirusesKoi herpesviruses Koi herpesviruscarpKHVCostes et al., 2008PoxvirusesVACCottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011CoronavirusesTransmissible gastroenteritisTGCVAllmazan et al., 2000		feline	FHV-1	Costes et al., 2006; Tai et al., 2010
Turkey herpesvirus β-Herpesviruses - Cytomegaloviruses Human cytomegalovirus human hCMV Borst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008 Rhesus cytomegalovirus Rhesus cytomegalovirus Guinea pig cytomegalovirus - Roseoloviruses Human herpesvirus 6 Lymphocryptoviruses Epstein-Barr virus Rhesus rhadinovirus Rhesus rhadinovirus Rhesus marine RSHV Delecluse et al., 1998 - Rhadinovirus Rhesus rhadinovirus RW Estep et al., 2007 MHV-68 Adler et al., 2007 MHV-68 Adler et al., 2007 MHV-68 Adler et al., 2007 MHV-68 Allorepesvirus saimiri Saimiriine RW Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Coronaviruses Transmissible gastroenteritis Porcine TGCV Almazan et al., 2000				
β-Herpesviruses - CytomegalovirusHuman cytomegalovirushumanhCMVBorst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008Rhesus cytomegalovirusrhesusrhCMVChang & Barry, 2003Murine cytomegalovirusmurinemCMVMesserle et al., 1997Guinea pig cytomegalovirusguinea piggpCMVMcGregor & Schleiss, 2001a- RoseoloviruseshumanHHV-6Borenstein & Frenkel, 2009γ-HerpesvirusesLymphocryptoviruses- LymphocryptovirusesEpstein-Barr virushumanEBVDelecluse et al., 1998- RhadinovirusesKSHVDelecluse et al., 2001; Zhou et al., 2002herpesvirusRRVEstep et al., 2007Murine γ-herpesvirus 68murineMHV-68Adler et al., 2000; Song et al., 2005Herpesvirus saimirisaimiriineHVSWhite et al., 2003; Toptan et al., 2010AlloherpesvirusescarpKHVCostes et al., 2008KHVCostes et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011Cowpox virusbovineCPXVAlmazan et al., 2010		turkey		Schumacher et al., 2000
- Cytomegaloviruses Human cytomegalovirus Human cytomegalovirus Human cytomegalovirus Rhesus cytomegalovirus Rhesus cytomegalovirus Murine cytomegalovirus Murine cytomegalovirus Murine cytomegalovirus Murine cytomegalovirus Guinea pig cytomegalovirus - Roseoloviruses Human herpesvirus 6 Human herpesvirus 6 - Lymphocryptoviruses Epstein-Barr virus - Rhadinoviruses Kaposi-Sarcoma associated human Rhesus rhadinovirus Rherpesvirus 8 Human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Relepted al., 2007 MHV-68 Herpesvirus saimiri Alloherpesviruses Koi herpesvirus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Coronaviruses Transmissible gastroenteritis Porcine TGCV Almazan et al., 2000	Turkey herpesvirus	turkey	HVT	Baigent et al., 2006
Human cytomegalovirushumanhCMVBorst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008Rhesus cytomegalovirusrhesusrhCMVMurphy et al., 2003; Sinzger et al., 2008Murine cytomegalovirusmurinemCMVMesserle et al., 1997Guinea pig cytomegalovirus - Roseolovirusesguinea piggpCMVMcGregor & Schleiss, 2001a- Herpesviruses- Lymphocryptoviruses- LymphocryptovirusesEpstein-Barr virushumanEBVDelecluse et al., 1998- RhadinoviruseshumanKSHVDelecluse et al., 2001; Zhou et al., 2002Resus rhadinovirusrhesusRRVEstep et al., 2007Murine γ-herpesvirus 68murineMHV-68Adler et al., 2000; Song et al., 2005Herpesvirus saimirisaimiriineHVSWhite et al., 2003; Toptan et al., 2010AlloherpesvirusesKHVCostes et al., 2008Koi herpesviruscarpKHVCostes et al., 2008PoxvirusesVACCottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011CoronavirusesCoronavirusesTransmissible gastroenteritisTGCVAlmazan et al., 2000				
Rhesus cytomegalovirus Rhesus cytomegalovirus Murine cytomegalovirus Rurine cytomegalovirus Rurine guinea pig cytomegalovirus Rurine guinea pig cytomegalovirus Rurine pig cytomegalovitus Rurine pig cytomegalov	- Cytomegaloviruses			
Rhesus cytomegalovirus rhesus rhCMV Chang & Barry, 2003 Murine cytomegalovirus guinea pig gpCMV Messerle et al., 1997 Guinea pig cytomegalovirus guinea pig gpCMV McGregor & Schleiss, 2001a - Roseoloviruses Human herpesvirus 6 human HHV-6 Borenstein & Frenkel, 2009 - Herpesviruses - Lymphocryptoviruses Epstein-Barr virus human EBV Delecluse et al., 1998 - Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus Rhesus rhadinovirus Murine γ-herpesvirus 68 murine Herpesvirus saimiri saimiriine HVS White et al., 2000; Song et al., 2005 Herpesviruses Koi herpesvirus KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Coronaviruses Transmissible gastroenteritis TGCV Almazan et al., 2000	Human cytomegalovirus	human	hCMV	Borst et al., 1999; Dulal et al., 2009; Hahn
Rhesus cytomegalovirusrhesus murine guinea pig cytomegalovirusrhesus murine guinea pig cytomegalovirusrhesus mCMV guinea pig gpCMVChang & Barry, 2003 Messerle et al., 1997 McGregor & Schleiss, 2001a- Roseoloviruses Human herpesviruseshumanHHV-6Borenstein & Frenkel, 2009γ-Herpesviruses- Lymphocryptoviruses- Epstein-Barr virus - RhadinoviruseshumanEBVDelecluse et al., 1998Kaposi-Sarcoma associated herpesvirushumanKSHVDelecluse et al., 2001; Zhou et al., 2002Rhesus rhadinovirus Murine γ-herpesvirus 68 Herpesvirus saimirirhesus murine saimiriineRRV MHV-68Estep et al., 2007 Adler et al., 2000; Song et al., 2005 HVSHerpesviruses Koi herpesviruscarpKHVCostes et al., 2008PoxvirusesVACCottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Roth et al., 2011Covpox virusbovineCPXVAlmazan et al., 2000				et al., 2002, 2003; Marchini et al., 2001;
Murine cytomegalovirusmurine guinea pig gycMVmCMV gpCMVMesserle et al., 1997 McGregor & Schleiss, 2001a- Roseoloviruses Human herpesvirus 6 - Lymphocryptoviruses - Epstein-Barr virus - RhadinoviruseshumanHHV-6Borenstein & Frenkel, 2009- Rhadinoviruses - Rposi-Sarcoma associated herpesvirus Rhesus rhadinovirus - Murine γ-herpesvirus 68 - Herpesvirus saimirihuman rhesus murine saimiriineKSHV - Belecluse et al., 2001; Zhou et al., 2002- RRV - Roseolovirus - Rhadinovirus - Rhadinovirus - Rhesus rhadinovirus - Rhesus rhadinovirus - Rhesus rhadinovirus - Rurine γ-herpesvirus 68 - Herpesvirus saimiriRRV - Estep et al., 2007 - Adler et al., 2000; Song et al., 2005 - Adler et al., 2003; Toptan et al., 2010- Alloherpesviruses - Koi herpesviruscarpKHVCostes et al., 2008- Roviruses - Vaccinia virusVAC - Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011- Coronaviruses - Transmissible gastroenteritisDorcineTGCVAlmazan et al., 2000				Murphy et al., 2003; Sinzger et al., 2008
Guinea pig cytomegalovirus Roseoloviruses Human herpesvirus 6 human HHV-6 Borenstein & Frenkel, 2009 γ-Herpesviruses - Lymphocryptoviruses Epstein-Barr virus human EBV Delecluse et al., 1998 - Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus RHV-68 HHV-68 HHV-68 HHV-68 Adler et al., 2007 White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Coronaviruses Transmissible gastroenteritis Porcine TGCV Almazan et al., 2000		rhesus		
- Roseoloviruses Human herpesvirus 6 human HHV-6 Borenstein & Frenkel, 2009 γ-Herpesviruses - Lymphocryptoviruses Epstein-Barr virus human EBV Delecluse et al., 1998 - Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus rhesus RRV Estep et al., 2007 Murine γ-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000		murine	mCMV	Messerle et al., 1997
Human herpesvirus 6humanHHV-6Borenstein & Frenkel, 2009γ-Herpesviruses- LymphocryptovirusesEpstein-Barr virushumanEBVDelecluse et al., 1998- Rhadinoviruses- RhadinovirusesKaposi-Sarcoma associated humanKSHVDelecluse et al., 2001; Zhou et al., 2002herpesvirusrhesus rhadinovirusRRVEstep et al., 2007Murine γ-herpesvirus 68murineMHV-68Adler et al., 2000; Song et al., 2005Herpesvirus saimirisaimiriineHVSWhite et al., 2003; Toptan et al., 2010AlloherpesvirusesKHVCostes et al., 2008Koi herpesviruscarpKHVCostes et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011Cowpox virusbovineCPXVRoth et al., 2011CoronavirusesTGCVAlmazan et al., 2000		guinea pig	gpCMV	McGregor & Schleiss, 2001a
γ-Herpesviruses - Lymphocryptoviruses Epstein-Barr virus human EBV Delecluse et al., 1998 - Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus rhesus RRV Estep et al., 2007 Murine γ-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000				
- Lymphocryptoviruses Epstein-Barr virus human EBV Delecluse et al., 1998 - Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus rhesus RRV Estep et al., 2007 Murine γ-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Human herpesvirus 6	human	HHV-6	Borenstein & Frenkel, 2009
Epstein-Barr virus human EBV Delecluse et al., 1998 - Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus rhesus RRV Estep et al., 2007 Murine γ-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Covpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	γ-Herpesviruses			
- Rhadinoviruses Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus rhesus RRV Estep et al., 2007 Murine γ-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	- Lymphocryptoviruses			
Kaposi-Sarcoma associated human KSHV Delecluse et al., 2001; Zhou et al., 2002 herpesvirus Rhesus rhadinovirus rhesus murine y-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Epstein-Barr virus	human	EBV	Delecluse et al., 1998
Rhesus rhadinovirus rhesus RRV Estep et al., 2007 Murine γ-herpesvirus 68 murine MHV-68 Adler et al., 2000; Song et al., 2005 Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	- Rhadinoviruses			
Rhesus rhadinovirusrhesus murine γ-herpesvirus 68 Herpesvirus saimiriRRV murine saimiriineEstep et al., 2007 MHV-68 HVSAdler et al., 2000; Song et al., 2005 White et al., 2003; Toptan et al., 2010Alloherpesviruses Koi herpesviruscarpKHVCostes et al., 2008PoxvirusesVACCottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011Cowpox virusbovineCPXVRoth et al., 2011CoronavirusesTransmissible gastroenteritisporcineTGCVAlmazan et al., 2000	Kaposi-Sarcoma associated	human	KSHV	Delecluse et al., 2001; Zhou et al., 2002
Murine γ-herpesvirus 68murineMHV-68Adler et al., 2000; Song et al., 2005Herpesvirus saimirisaimiriineHVSWhite et al., 2003; Toptan et al., 2010AlloherpesvirusesKoi herpesviruscarpKHVCostes et al., 2008PoxvirusesVACCottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011Cowpox virusbovineCPXVRoth et al., 2011CoronavirusesTransmissible gastroenteritisporcineTGCVAlmazan et al., 2000	herpesvirus			
Herpesvirus saimiri saimiriine HVS White et al., 2003; Toptan et al., 2010 Alloherpesviruses Koi herpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000		rhesus	RRV	Estep et al., 2007
Alloherpesviruses Koi herpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Murine γ-herpesvirus 68	murine	MHV-68	Adler et al., 2000; Song et al., 2005
Koi herpesvirus carp KHV Costes et al., 2008 Poxviruses Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Herpesvirus saimiri	saimiriine	HVS	White et al., 2003; Toptan et al., 2010
PoxvirusesVaccinia virusVACCottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011Cowpox virusbovineCPXVRoth et al., 2011CoronavirusesTransmissible gastroenteritisporcineTGCVAlmazan et al., 2000	Alloherpesviruses			
Vaccinia virus VAC Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011 Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Koi herpesvirus	carp	KHV	Costes et al., 2008
Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Poxviruses			
Cowpox virus bovine CPXV Roth et al., 2011 Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Vaccinia virus		VAC	Cottingham et al., 2008; Domi & Moss,
Coronaviruses Transmissible gastroenteritis porcine TGCV Almazan et al., 2000				2002; Meissinger-Henschel et al., 2011
Transmissible gastroenteritis porcine TGCV Almazan et al., 2000	Cowpox virus	bovine	CPXV	Roth et al., 2011
	Coronaviruses			
compositions	Transmissible gastroenteritis	porcine	TGCV	Almazan et al., 2000
COLOHAVILUS	coronavirus	-		
Severe acute respiratory human SARS Almazan et al., 2006	Severe acute respiratory	human	SARS	Almazan et al., 2006
syndrome coronavirus CoV			CoV	
Čoronavirus OC43 human OC43 St. Jean et al., 2006		human	OC43	St. Jean et al., 2006
Coronavirus NL63 human NL63 Donaldson et al., 2008	Coronavirus NL63	human	NL63	

Table 1. List of cloned viral bacterial artificial chromosomes with key references.

3. Manipulation of viral bacterial artificial chromosomes

The generation of a molecular viral BAC clone forms the prerequisite for efficient virus mutagenesis. The site-directed manipulation of single-copy plasmid DNA in *E. coli* by homologous recombination was established in several conditionally or transiently expressed forms. Alternatively, transposon mutagenesis can be used as a non-directed random method.

3.1 Site-directed mutagenesis of viral bacterial artificial chromosomes

Common techniques for the rapid and targeted DNA mutagenesis are based on Red recombination or RecET cloning encoded by prophages λ or Rac, respectively (Court et al., 2002; Lee et al., 2001; Murphy, 1998; Muyrers et al., 1999, 2001, 2004; Yu et al., 2000; Zhang et al., 1998). Recombination-mediated genetic engineering (termed "recombineering") via Red and RecET allows almost unlimited modifications of large BAC-cloned DNA sequences in *E.* coli and is widely used in functional genomics (Copeland et al., 2001; Muyrers et al., 2001; Narayanan et al. 1999; Sawitzke et al., 2007; Sharan et al., 2009; Thomason et al., 2007; Warming et al., 2005). The Red-recombination system from phage λ consists of the 5'-3'exonuclease Exo and of the single-strand (ss) DNA-binding protein Beta. These proteins mediate the recombination between dsDNA ends and homologous target sequences on replicating DNA molecules in E. coli and are biologically responsible for the integration of λ phage DNA into the bacterial chromosome (Carter & Radding, 1971). Exo acts on dsDNA ends to generate 3'-ssDNA sticky ends (Little, 1967). Then, Beta recognizes the recessed ssDNA ends and anneals them to complementary ssDNA in preformed replication forks leading to their recombination with the homologous sequence (Kmiec & Holloman, 1981; Muniyappa & Radding, 1986). The Red genes are expressed together with the λ gam gene under a temperature-inducible promoter for the efficient induction and DNA manipulation in bacteria. Gam is a natural inhibitor of the E. coli RecBCD exonuclease, which rapidly degrades dsDNA invading into bacteria (Karu et al., 1975; Murphy, 1991, 1998, 2007; Yu et al., 2000).

While the Red recombination system is expressed, a linear DNA fragment with 40-50 bp homologous flanking regions is inserted into to the selected target sequence by Exo and Beta, whereas Gam blocks the RecBCD enzyme from degrading dsDNA ends. The Red system does not need the E. coli RecA protein, which is the main endogenous mediator of homologous recombination in E. coli (Murphy, 1998; Yu et al., 2000). Therefore, the Red recombination is useful for the easy manipulation of plasmids or bacterial chromosomes in a recA-recombination-deficient E. coli background (e.g., DY380-derived strains or GS1783) by linear products of the polymerase chain-reaction (PCR) that were generated with primers containing short homologous target sequences at their 5'-ends (Copeland et al., 2001; Oppenheim et al., 2004; Yu et al., 2000). The application of Red-mediated DNA mutagenesis for BAC mutagenesis was greatly simplified by expressing the red and gam genes from a defective prophage integrated in the E. coli-genome, when the culture temperature is increased from 32 to 42°C, without the need for additional expression plasmids. In comparison to the plasmid coexpression strategy, the λ prophage system is up to 100-fold more efficient in Red recombineering and the Red protein expression is more tightly controlled under the temperature-inducible promoter of the λ prophage (Lee et al., 2001; Yu et al., 2000). This more stringent control also reduces the risk for unwanted recombination

during bacterial DNA replication. During the mutagenesis procedure, the mutation of interest is introduced into the target sequence together with an antibiotic resistance gene. The selection marker may be flanked by recombinase recognition sites in order to allow its secondary excision from the recombinants (Lee et al., 2001; Yu et al., 2000). The remaining single copy of a recombinase recognition site limits further repeated steps of the procedure and may also interfere with gene functions in tightly packed genomes. The site-directed mutagenesis may be used to delete further non-essential regions if the cloning capacity is limited in particularly large virus genomes. In addition, genetic elements of the BAC constructs can even be moved within the BAC by site-directed mutagenesis to optimized insertion positions (Wussow et al., 2009).

3.2 Two-step en passant mutagenesis

By the combination of homologous recombination steps, "traceless", "seamless", or "markerless" recombineering strategies were developed which allow the highly efficient mutagenesis of BAC DNA in E. coli without retaining any operational sequences (Sawitzke et al., 2007; Sharan et al., 2009; Thomason et al., 2007; Tischer et al., 2006, 2010a, b; Warming et al., 2005). The en passant procedure combines Red recombination with cleavage by the homing endonuclease I-SceI (Tischer et al., 2006, 2010a, b). The asymmetrical 18 bp I-SceI recognition site can be inserted into plasmid DNA and cleaved after induced expression of the homing enzyme. This highly sequence-specific restriction endonuclease produces dsDNA ends accessible for homologous recombination (Jamsai et al., 2003). For the en passant protocol, large oligonucleotide primers are designed which allow generation of a PCR product for the Red-mediated insertion of a selection marker together with an I-SceI recognition site flanked by a 50 bp direct sequence duplication. After selection of recombinants, a double-strand break is induced by I-SceI cleavage at the respective recognition site. This permits the seamless excision of the positive selection marker (psm) by a second Red-mediated homologous recombination event via short duplicated sequences. En passant mutagenesis can be used to generate single point-mutations, substitutions, deletions, or insertions, e.g., of expression constructs, epitope tags, or autofluorescent fusion proteins (Figure 2). For the generation of single point mutations, a fragment including a psm and an I-SceI site is amplified with primers adding 60-80 bp extensions to the psm-I-SceI unit. The distal 40-50 bp of the primer sequences and of the resulting PCR fragments are homologous to the target site in the BAC. Additionally, 40-50 bp of the mutated target site are included into both primers in reverse complementary orientation. The psm fragment with the appropriate flanking sequence duplication and point mutation is inserted into the site of interest by the first Red recombination step. After induction of I-SceI cleavage, the psm is excised between the duplicated sequences and the markerless point mutation is generated by the second Red recombinetion step (Figure 2A). Similar procedures are used for large deletions. In this case, the PCR-primers for psm-I-SceI amplification carry 5'extensions from the up- and downstream regions flanking the deletion area (Figure 2C). For the seamless insertion of large sequences by *en passant* mutagenesis, a cassette containing the psm and the I-SceI site and a 40-50 bp sequence duplication is PCR amplified. This PCR fragment is then inserted into a unique restriction endonuclease site of the cloned sequence of interest. The fragment is released from the plasmid by terminal restriction endonuclease sites and used for the precise insertion into the target region by Red recombination. In selected recombinants, the psm is seamlessly removed by the second en passant recombination of the 50 bp duplication of the inserted sequence of interest (Figure 2B).




Fig. 2. *En passant* mutagenesis. A) Point mutation. A positive selection marker (psm) and an I-SceI site are PCR-amplified with primers carrying 60-80 bp homologous extensions (coloured elements). In both primers, 40-50 bp (red and blue) around the core sequence are reverse complementary and carry the mutation (triangles). The PCR product is inserted into the target site by Red recombination. After a double-strand break by I-SceI, the psm is excised by Red recombination of the duplication, resulting in the precise point mutation. B) Insertion of large sequences. The psm-I-SceI cassette is amplified using one primer with a 40-50 bp duplication (yellow) and inserted into a unique restriction site (*) of a cloned sequence of interest (soi). The soi transfer construct is then amplified using primers with 40-50 bp extensions (red and blue) and inserted into the target site by Red recombination. After I-SceI and red expression, the psm is deleted from soi by recombination of the short duplications. C) Large deletion. The psm-I-SceI element is amplified using primers with 5'-ends homologous to adjacent sequences from the deletion region (coloured). The soi is then deleted by Red recombination. The procedure follows the further steps as in panel A (adapted from Tischer et al., 2006; Felix Wussow, Ph.D. thesis, Christian Albrecht University of Kiel, 2009).

The well-established and highly versatile markerless manipulation techniques allow for the repetitive manipulation of the cloned genomes even within the direct or inverted viral repeat sequences. This unique feature makes the BAC technology especially useful to mutagenize elements involved in DNA replication or maturation, *e.g.*, the origin of DNA replication or DNA packaging signals, which are usually present in the repeat sequences or in the genomic termini of herpesviral genomes. Similarly, many DNA elements relevant for the establishment of latency and the reactivation from the latent state as well as for the integration of the viral DNA into the host genome are located in the viral repeats and can be efficiently studied by the BAC technology.

The *en passant* mutagenesis strategy can also be used for the seamless removal of the BAC-vector sequences from the viral genomes during virus reconstitution in eukaryotic cells

(Figure 3). Appropriately designed viruses will delete the mini-F element due to homologous recombination of duplications of viral genome fragments or due to intrinsic genome features. Such strategies were based on genomic duplications engineered in direct orientation at either site of the vector elements (Strive et al., 2007; Wagner et al., 1999). However, such BACs with direct duplications can apparently not be stably maintained in *E. coli* with the temperature-inducible Red expression cassette on a defective λ prophage integrate, since the mini-F vector will be lost presumably by homologous recombination between the duplicated viral sequences, even in the non-induced state. This has been overcome by providing the ET cloning functions from an additionally transfected plasmid for the efficient removal function after the mutagenesis procedure (Strive et al., 2007; Wagner et al., 1999), although recombineering mediated by plasmid-encoded functions is up to 100-fold less efficient than the integrated λ prophage system (Lee et al., 2001; Muyrers et al., 1999; Narayanan et al., 1999; Yu et al., 2000). In another λ -based self-excision system (Figure 3), the duplicated viral sequences flanking the mini-F integration site were inserted in inverse orientation. This arrangement allowed the stable maintenance of the BAC DNA in




Fig. 3. Self-excision of BAC sequences by stabilized genomic duplication. A) BAC vector (green) self-excision from the viral DNA (black) by a forward genomic duplication (yellow to red gradient bars) inserted between the mini-F replicon (mFr) and the antibiotic resistance gene (arg). Two recombination events are necessary to release the mFr or the arg from the viral DNA. B) Self-excision of the BAC sequences from the viral DNA by a genomic duplication inserted in inverse orientation into the vector elements. Two successive events of recombination are required for the complete BAC vector excision from the viral DNA (adapted from Felix Wussow, Ph.D. thesis, Christian Albrecht University of Kiel, 2009).

E. coli, since two successive events of homologous recombination would be required for the deletion of the complete BAC sequences. BACs with these inverse viral duplications flanking the mini-F integration site within a viral direct S-repeat area did not lead to any detectable BAC instability in the recombineering *E. coli* strain GS1783 and allowed the efficient deletion of the vector moiety (Tischer et al., 2007).

Mini-F vector sequences containing inverse genomic duplications that were inserted into different essential viral replication genes also allow the efficient mini-F vector self-excision. Alternatively, certain repeat regions or terminal virus sequences are suitable under specific conditions for the autonomous vector excision (Tischer et al., 2007; Wussow et al., 2009; Zhou et al., 2010). Different genomic insertion sites for the mini-F vector were compared for the seamless reconstitution of recombinant virus. The most efficient variant pHJOFpac

carried the mini-F vector insertion at the terminal genomic junction of VZV, which is an optimal vector integration site permitting the rapid and spontaneous generation of recombinant progeny devoid of any vector elements (Wussow et al., 2009). A similar integration site was described for rhesus rhadinovirus (RVV), from which the vector is also efficiently released (Zhou et al., 2010). Therefore, the terminal genomic junction might be in general an optimal integration site for the mini-F vector to construct other large linear viral DNA genomes as infectious BACs. In addition, the recombineering methodology even allows the transposition of genetic elements to defined new locations within the same BAC molecule (Wussow et al., 2009). Thus, the mini-F-transposition strategy eliminated the last hurdle to perform any imaginable kind of targeted seamless BAC modifications in *E. coli*. This is in general a valuable tool to reorganize or repair any other established BACs, *e.g.*, for the development of gene therapy or vaccine vectors or of specific targeting vectors for conditional knock-out mice.

3.3 Transposon mutagenesis of viral BACs

Alternatively, the random and non-directed approach of transposon mutagenesis was adapted for virus BAC mutagenesis (Brune et al., 1999; Smith & Enquist, 1999) and provides saturated libraries of diverse recombinant mutants. The random transposon mutagenesis was successfully performed for the large genomes of hCMV, mCMV, equine herpesvirus type 1 (EHV-1), and murine herpesvirus type 68 (MHV-68) (Bubeck et al., 2003; Hansen et al., 2006; Hobom et al., 2000; Song et al., 2005; Yu et al., 2003). Fortunately, the transposon insertion occurs preferentially into plasmid DNA in comparison to the bacterial genome. After transposon mutants have been tested for their functional phenotype, the respective genotype must be determined. This is accomplished using PCR primers which bind to the transposon insert and allow an easy genome-wide mapping and specific sequencing from the viral BAC genome. The major advantages of transposon mutagenesis are the unbiased random approach and the rapid generation of large BAC mutant libraries. However, this may be complicated by multiple insertions in the same BAC or by an uneven distribution of the insertion sites over the virus genome.

3.4 Functional mutagenesis of specific viral BACs

BAC generation and mutagenesis has been reported on numerous viruses (Table 1). HSV-1, the prototype genome of the herpesviruses in general, as well as of the α-herpesviruses and simplexviruses in particular, exists as BACs from different virus strains (Horsburgh et al., 1999a, b; Nagel et al., 2008; Saeki et al., 1998; Stavropoulos & Strathdee, 1998; Tanaka et al., 2003). Many BAC-based studies were performed on mutations in HSV-1 genes (*e.g.*, Boutell et al., 2002; Leege et al., 2009; O'Hara et al., 2010; Roberts et al., 2009; Tong & Stow, 2010). Also, HSV-2 is available as a viral BAC (Meseda et al., 2004). Several strains of the highly cell-associated varicellovirus prototype, VZV, were cloned as infectious BACs, the vaccine and parental OKA strains, as well as the wild-type isolate HJO (Nagaike et al., 2004; Tischer et al., 2007; Wussow et al., 2009; Yoshii et al., 2008; Zhang et al., 2007, 2008). A VZV BAC with a luciferase reporter gene allowed viral replication studies *in vivo* (Zhang et al., 2007, 2008). VZV was also subjected to saturating mutagenesis for determining essential genes for viral replication (Zhang et al., 2010). The genome of the closely related simian varicella virus (SVV) of rhesus monkeys has also been made available as a BAC (Brazeau et al., 2011; Gray et al., 2011). Pseudorabies virus (PrV) is another varicellovirus with highly important model

function for herpesvirus biology. PrV was cloned as a BAC and used for pathogenesis studies *in vivo* (Smith & Enquist, 1999, 2000; Fuchs et al., 2009; Kopp et al., 2004]. Additional varicellovirus BACs of various animals have been studied *in vitro* and *in vivo*: Bovine herpesvirus type 1 (BHV-1; Gabev et al., 2009; Mahony et al., 2002; Robinson et al., 2008; Trapp et al., 2003), EHV-1 (Goodman et al., 2007; Rudolph & Osterrieder, 2002; Rudolph et al., 2002; Yao et al., 2003), canine herpesvirus (CHV; Strive et al., 2006), and feline herpesvirus type 1 (FHV-1; Costes et al., 2006; Richter et el., 2009; Tai et al., 2010). Moreover, BACs exist for the mardiviruses Marek's disease virus (MDV) and herpesvirus of turkeys (HVT) (Baigent et al., 2006; Petherbridge et al., 2003; Schumacher et al., 2000; Zhao et al., 2008). The particularly large BAC-cloned koi herpesvirus belongs to the alloherpesviruses and not to the typical α - to γ -herpesviruses (Costes et al., 2008, 2009).

The prototype for the β-herpesviruses, hCMV, has the largest genome among the human herpesviruses containing approximately 165 genes. Clinical hCMV isolates have larger genomes and replicate well in macrophages and endothelia cells, whereas the laboratory strains have undergone deletions and replicate efficiently only in fibroblasts (Dolan et al., 2004). Therefore, after the laboratory strain AD169, various laboratory strains and clinical isolates were cloned as infectious BACs in order to provide defined genetic conditions for functional studies (Borst et al., 1999; Dulal et al., 2009; Hahn et al., 2002, 2003; Marchini et al., 2001; Murphy et al., 2003; Sinzger et al., 2008). Many functional studies were performed with hCMV BACs (e.g., Britt et al., 2004; Spaderna et al., 2005). Saturating random mutagenesis over the entire hCMV genome was performed by transposon insertion (Hobom et al., 2000; Yu et al., 2003). Moreover, the necessity for virus replication was determined for 162 individual hCMV genes (Dunn et al., 2003). mCMV as an important animal model for hCMV pathogenesis was the first herpesvirus genome to be cloned as an infectious BAC (Messerle et al., 1997) which has been used for in vitro and in vivo mCMV studies (e.g., Wagner et al., 1999; Cicin-Sain et al., 2003, 2007; Menard et al., 2003; Schnee et al., 2006). BAC-clones have also been constructed for the genomes of rhesus CMV (rhCMV; Chang & Barry, 2003; Lilja et al., 2008; Rue et al., 2004) and guinea-pig CMV (gpCMV; Crumpler et al., 2009; McGregor & Schleiss, 2001a; Schleiss, 2008). The BAC of the human roseolovirus HHV-6 is still dependent on a helper virus infection (Borenstein & Frenkel, 2009; Borenstein et al., 2010).

The oncogenic γ-herpesvirus and lymphocryptovirus EBV (Delecluse et al., 1998) was one of the first cloned viral BACs and many studies have applied this technique, *e.g.*, on oncogene functions (Ahsan et al., 2005; Anderton et al., 2008; Chen et al., 2005; Kanda et al., 2004). The oncogenic rhadinovirus KSHV is hampered by its non-efficient replication in cell culture. Also for KSHV, several BACs were constructed and applied for functional analyses (Delecluse et al., 2001; Fan et al., 2006; Lu et al., 2010; Lukac et al., 2001; Luna et al., 2004; Majerciak et al., 2007; Xu et al., 2005, 2006; Yakushko et al., 2011 Zhou et al., 2002). Additionally, the major rhadinovirus animal model viruses were cloned in BACs, such as RRV (Estep et al., 2007; Zhou et al., 2010), MHV-68 (Adler et al., 2000; Pavlova et al., 2003), and herpesvirus saimiri (HVS; Calderwood et al., 2005; Toptan et al., 2010; White et al., 2003, 2007).

Besides the herpesviruses, BAC-cloning has been successfully applied for the poxvirus Vaccinia virus (Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011) and cowpox virus (Roth et al., 2011). Moreover, this method was useful to generate full-length molecular clones of the large RNA genomes of different coronaviruses such as the

porcine virus of transmissible gastroenteritis, the severe acute respiratory syndrome coronavirus and the human coronaviruses NL63 and OC43 (Almazan et al., 2000, 2006; Donaldson et al., 2008; St. Jean et al., 2006).

4. Conclusion

The viral DNA replication strategies were very well exploited for the generation of efficient BAC cloning, mutagenesis and reconstitution techniques. BAC cloning and recombineering strategies are essential for the efficient mutagenesis and analysis of herpesviral and poxviral gene functions and reduce problems due to unwanted mutations outside of the region of interest. In addition, only the existence of a cloned full-length genome guarantees the usage of defined genome structures, especially in variable virus genes. For example, the BAC-mediated expression of fusion proteins of viral factors with autofluorescent moieties can be used for analysing the expression and localization patterns of viral functions (e.g., Antinone & Smith, 2006). The precise, seamless, and repetitive manipulation of repeat regions may facilitate the study of viral DNA elements involved in DNA replication, genome maturation, and packaging, as well as in latency, reactivation, and chromosomal integration.

Besides basic research, the BAC technology has its major translational applications in vector and vaccine development. In the case of viral vector design, the recombineering technique allows the easy deletion of useless non-essential regions or virulence genes from the viral vector genome (e.g., Cicin-Sain et al., 2007). This may reduce unwanted side-effects and may increase the cloning potential for transgenes. Even large and complex multi-unit transgene cassettes can be inserted as well as novel conditional replication and expression control systems (e.g., Glass et al., 2009). Such viral vectors include optimized transgene cassettes, the lack of genomic integration, and the advantage of physiologic infection routes. This may also comprise cell-type specific functions as for example in EBV or HVS vectors for B- or T-lymphocytes, respectively. Viral vectors may be constructed as efficiently replicating oncolytic agents (Kuroda et al., 2006; Marconi et al., 2009; Terada et al., 2006) or as packaging-cell dependent transduction vehicles (e.g., Hettich et al., 2006).

The BAC technology has also provided new possibilities for vaccine development. For example, EHV-1 BAC-derived viruses were constructed for immunization against West Nile virus, bovine diarrhea virus or Venezuelan equine encephalitis virus (Rosas et al., 2007a, b, 2008). Especially for possible vaccination strategies for hCMV, the detailed analysis of the animal model viruses is important. In the case of mCMV and gpCMV, such BAC-based immunization strategies have shown promising results (Cicin-Sain et al., 2003, 2007; Crumpler et al., 2009; Redwood et al., 2005). In the rhesus monkey model, the viral inhibition mechanism for secondary rhCMV infections suggests respective strategies for hCMV vaccines (Hansen et al., 2010). Such observations may lead the way to novel recombinant human vaccines, for example by replication-deficient hCMV or HSV-1 (Schleiss et al., 2006; Suter et al., 1999).

Although the highly efficient modified vaccinia virus Ankara (MVA) has already been well established as a vaccine for the application in humans, the BAC strategy shows considerable advantage for optimizing novel vaccine generations (Cottingham et al., 2008; Domi & Moss, 2002; Meissinger-Henschel et al., 2011; Roth et al., 2011), especially since MVA and related

poxviruses are also useful as transgene vectors for the efficient immunization against heterologous pathogens.

5. Acknowledgements

The scientific work underlying this manuscript was supported by the Deutsche Forschungsgemeinschaft, the Excellence Cluster Inflammation at Interfaces, the Wilhelm Sander-Stiftung, and the Varicella-Zoster Virus Research Foundation. The authors thank Dr. Karsten Tischer for fruitful collaboration.

6. References

- Adler, H.; Messerle, M.; Koszinowski, U.H. (2001). Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. *Journal of Virology*, Vol.75, No. X, 5692-5696
- Adler, H.; Messerle, M.; Koszinowski, U.H. (2003). Cloning of herpesviral genomes as bacterial artificial chromosomes. *Reviews in Medical Virology*, Vol.13, No.12, 111-121
- Adler, H.; Messerle, M.; Wagner, M.; Koszinowski, U.H. (2000). Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. *Journal of Virology*, Vol.74, No.15, pp. 6964-6974
- Ahsan, N.; Kanda, T.; Nagashima, K.; Takada, K. (2005). Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. *Journal of Virology*, Vol.79, No.7, pp. 4415-4424
- Ali, A.K.; Saito, S.; Shibata, S.; Takada, K.; Kanda, T. (2009). Distinctive effects of the Epstein-Barr virus family of repeats on viral latent gene promoter activity and B-lymphocyte transformation. *Journal of Virology*, Vol.83, No.18, pp. 9163-9174
- Almazan, F.; DeDiego, M.L.; Galan, C.; Escors, D.; Alvarez, E.; Ortego, J.; Sola, I.; Zuniga, S.; Alonso, S.; Moreno, J.L.; Nogales, A.; Capiscol, C.; Enjuanes, L. (2006). Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. *Journal of Virology*, Vol.80, No.21, 10900-10906
- Almazan, F.; Gonzalez, J.M.; Penzes, Z.; Izeta, A.; Calvo, E.; Plana-Duran, J.; Enjuanes, L. (2000). Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.97, No.10, 5516-5521
- Anderton, E.; Yee, J.; Smith, P.; Crook, T.; White, R. E.; Allday, M.J. (2008). Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. *Oncogene*, Vol.27, No.4, pp. 421-433
- Antinone, S. E.; Smith, G.A. (2006). Two modes of herpesvirus trafficking in neurons: membrane acquisition directs motion. *Journal of Virology*, Vol.80, No.22, pp. 11235-11240
- Baigent, S.J.; Petherbridge, L.J.; Smith, L.P.; Zhao, Y.; Chesters, P.M.; Nair, V.K. (2006). Herpesvirus of turkey reconstituted from bacterial artificial chromosome clones induces protection against Marek's disease. *Journal of General Virology*, Vol.87, No.4, pp. 769-776

- Borenstein, R.; Frenkel, N. (2009) Cloning human herpesvirus 6A genome into bacterial artificial chromosomes and study of DNA replication intermediates. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.106, No.45, pp. 19138-19143
- Borenstein, R.; Zeigerman, H.; Frenkel, N. (2010). The DR1 and DR6 first exons of human herpesvirus 6A are not required for virus replication in culture and are deleted in virus stocks that replicate well in T-cell lines. *Journal of Virology*, Vol.84, No.6, pp. 2648-2656
- Borst, E.M.; Hahn, G.; Koszinowski, U.H.; Messerle, M. (1999) Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. *Journal of Virology*, Vol.73, No.10, pp. 8320-8329
- Boutell, C.; Sadis, S.; Everett, R.D. (2002). Herpes simplex virus type 1 immediate-early protein ICP0 and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. *Journal of Virology*, Vol.76, No.2, pp. 841-850
- Brazeau, E; Wellish, M; Kaufer, B.B.; Tischer, B.K; Gray, W.; Zhou, F.; Osterrieder, N.; Hanlon, T.; Golive, A.; Hall, T.; Nair, S.; Owens, G. P.; Müller, N.H.; Cohrs, R.J.; Pugazhenthi, S.; Gilden, D.; Mahalingam, R. (2011) Simian varicella virus open reading frame 63/70 expression is required for efficient virus replication in culture. *Journal of Neurovirology*, (April 2011), published electronically ahead of print
- Britt, W.J. (2000). Infectious clones of herpesviruses: a new approach for understanding viral gene function. *Trends in Microbiology*, Vol.8, No.6, pp. 262-265
- Britt, W.J.; Jarvis, M.; Seo, J.Y.; Drummond, D.; Nelson, J. (2004). Rapid genetic engineering of human cytomegalovirus by using a lambda phage linear recombination system: demonstration that pp28 (UL99) is essential for production of infectious virus. *Journal of Virology*, Vol.78, No.1, pp. 539-543
- Brune, W.; Menard, C.; Hobom, U.; Odenbreit, S.; Messerle, M.; Koszinowski, U.H. (1999). Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis. *Nature Biotechnology*, Vol.17, No.4, pp. 360-364
- Brune, W.; Messerle, M.; Koszinowski, U.H. (2000). Forward with BACs new tools for herpesvirus genomics. *Trends in Genetics*, Vol.16, No.6, pp. 254-259
- Bubeck, A.; Wagner, M.; Ruzsics, Z.; Lötzerich, M.; Iglesias, M.; Singh, I.R.; Koszinowski, U.H. (2004). Comprehensive mutational analysis of a herpesvirus gene in the viral genome context reveals a region essential for virus replication. *Journal of Virology*, Vol.78, No.15, pp. 8026-8035
- Calderwood, M.; White, R.E.; Griffiths, R.A.; Whitehouse, A. (2005). Open reading frame 73 is required for herpesvirus saimiri A11-S4 episomal persistence. *Journal of General Virology*, Vol.86, No.10, pp. 2703-2708
- Carter, D.M.; Radding, C.M. (1971). The role of exonuclease and beta protein of phage lambda in genetic recombination. II. Substrate specificity and the mode of action of lambda exonuclease. *Journal of Biological Chemistry*, Vol.246, No.8, pp. 2502-2512
- Chang, W.L.; Barry, P.A. (2003). Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis. *Journal of Virology*, Vol.77, No.9, pp. 5073-5083
- Chen, A.; DiVisconte, M.; Jiang, X.; Quink, C.; Wang F. (2005). Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. *Journal of Virology*, Vol. 79, No. 7, pp. 4506-4509

- Cicin-Sain, L.; Brune, W.; Bubic, I.; Jonjic, S.; Koszinowski, U. H. (2003). Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. *Journal of Virology*, Vol. 77, No. 15, pp. 8249-8255
- Cicin-Sain, L.; Bubic, I.; Schnee, M.; Ruzsics, Z.M.; Mohr, C.; Jonjic, S.; Koszinowski, U.H. (2007). Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. *Journal of Virology*, Vol.81, No.24, pp. 13825-13834
- Cohen, J.I.; Seidel, K.E. (1993). Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.90, No.15, pp. 7376-7380
- Copeland, N.G.; Jenkins, N.A.; Court, D.L. (2001). Recombineering: a powerful new tool for mouse functional genomics. *Nature Reviews Genetics* Vol.2, No.10, 769-779
- Costes, B.; Fournier, G.; Michel B.; Delforge, C.; Raj, V.S.; Dewals, B.; Gillet, L.; Drion, P.; Body, A.; Schynts, F.; Lieffrig, F.; Vanderplasschen, A. (2008). Cloning of the koi herpesvirus genome as an infectious bacterial artificial chromosome demonstrates that disruption of the thymidine kinase locus induces partial attenuation in Cyprinus carpio koi. *Journal of Virology*, Vol.82, No.10, pp. 4955-4964
- Costes, B.; Thirion, M.; Dewals B.; Mast, J.; Ackermann, M.; Markine-Goriaynoff, N.; Gillet, L.; Vanderplasschen, A. (2006). Felid herpesvirus 1 glycoprotein G is a structural protein that mediates the binding of chemokines on the viral envelope. *Microbes and Infection*, Vol.8, No.11, pp. 2657-2667
- Costes, B.; Raj, V. S.; Michel, B.; Fournier, G.; Thirion, M.; Gillet, L.; Mast, J.; Lieffrig, F.; Bremont, M.; Vanderplasschen, A. (2009). The major portal of entry of koi herpesvirus in cyprinus carpio is the skin. *Journal of Virology*, Vol.83, No.7, pp. 2819-2830
- Cottingham, M.G.; Andersen, R.F.; Spencer, A.J.; Saurya, S.; Furze, J.; Hill, A.V.; Gilbert, S.C. (2008). Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One Vol.3, No.2, e1638
- Court, D.L.; Sawitzke, J.A.; Thomason, L.A. (2002) Genetic engineering using homologous recombination. *Annual Reviews in Genetics*, Vol.35, pp. 361-388.
- Crumpler, M.M.; Choi, K.Y.; McVoy, M.A.; Schleiss, M.R. (2009). A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly atenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. *Vaccine*, Vol.27, No.31, pp. 4209-4218
- Cunningham, C.; Davison, A. J. (1993). A cosmid-based system for constructing mutants of herpes simplex virus type 1. *Virology*, Vol. 197, No. 1, pp. 116-124
- Delecluse, H.J.; Hilsendegen, T.; Pich, D.; Zeidler, R.; Hammerschmidt, W. (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.95, No.14, pp. 8245-8250
- Delecluse, H.J.; Kost, M.; Feederle, R.; Wilson, L.; Hammerschmidt, W. (2001). Spontaneous activation of the lytic cycle in cells infected with a recombinant Kaposi's sarcoma-associated virus. *Journal of Virology*, Vol.75, No.6, pp. 2921-2928
- Dolan, A.; Cunningham, C.; Hector, R.D.; Hassan-Walker, A.F.; Lee, L.; Addison, C.; Dargan, D.J.; McGeoch, D.J.; Gatherer, D.; Emery, V.C.; Griffiths, P.D.; Sinzger, C.;

- McSharry, B.P.; Wilkinson, G.W.; Davison, A.J. (2004). Genetic content of wild-type human cytomegalovirus. *Journal of General Virology*, Vol.85, No.5, pp. 1301-1312
- Domi, A.; Moss, B. (2002). Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.99, No.19, pp. 12415-12420
- Donaldson, E.F.; Yount, B.; Sims, A.C.; Burkett, S.; Pickles, R.J.; Baric, R.S. (2008) Systematic assembly of a full-length infectious clone of human coronavirus NL63. Journal of Virology, Vol.82, No.23, pp. 11948-11957
- Dulal, K.; Zhang, Z.; Zhu, H. (2009) Development of a gene capture method to rescue a large deletion mutant of human cytomegalovirus. *Journal of Virological Methods*, Vol.157, No.2, pp. 180-187
- Dunn, W.; Chou, C.; Li, H.; Hai, R.; Patterson, D.; Stolc, V.; Zhu, H.; Liu, F. (2003). Functional profiling of a human cytomegalovirus genome. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.100, No.2, pp. 14223-14228
- Estep, R.D.; Powers, M.F.; Yen, B.K.; Li, H.; Wong, S.W. (2007). Construction of an infectious rhesus rhadinovirus bacterial artificial chromosome for the analysis of Kaposi's sarcoma-associated herpesvirus-related disease development. *Journal of Virology*, Vol.81, No.6, pp. 2957-2969
- Fan, X.Z.; Li, X.; Zhou, F.; Gao, S.J.; Yuan, Y. (2006). Functional characterization of Kaposi's sarcoma-associated herpesvirus ORF45 by bacterial artificial chromosome-based mutagenesis. *Journal of Virology*, Vol.80, No.24, pp. 12187-12196
- Feederle, R.; Bartlett, E.J.; Delecluse, H.J. (2010). Epstein-Barr virus genetics: talking about the BAC generation. *Herpesviridae*, Vol.1, No.1, 6.
- Fuchs, W.; Klupp, B.G.; Granzow, H.; Leege, T.; Mettenleiter, T.C. (2009). Characterization of pseudorabies virus (PrV) cleavage-encapsidation proteins and functional complementation of PrV pUL32 by the homologous protein of herpes simplex virus type 1. *Journal of Virology*, Vol.83, No.8, pp. 3930-3943
- Gabev, E.; Fraefel, C.; Ackermann, M.; Tobler, K. (2009). Cloning of bovine herpesvirus type 1 and type 5 as infectious bacterial artifical chromosomes. *BMC Research Notes*, Vol. 2, No. 209
- Glass, M.; Busche, A.; Wagner, K.; Messerle, M.; Borst, E. M. (2009). Conditional and reversible disruption of essential herpesvirus proteins. *Nature Methods*, Vol. 6, No. 8, pp. 577-579
- Goodman, L.B.; Loregian, A.; Perkins, G.A.; Nugent, J.; Buckles, E.L.; Mercorelli, B.; Kydd, J.H.; Palu, G.; Smith, K.C.; Osterrieder, N.; Davis-Poynter, N. (2007). A point mutation in a herpesvirus polymerase determines neuropathogenicity. *PLoS Pathogens*, Vol.3, No.11, pp. 1583-1592
- Gray, W.L.; Zhou, F.; Noffke, J.; Tischer, K.B. (2011) Cloning the simian varicella virus genome in E. coli as an infectious bacterial artificial chromosome. *Archives of Virology*, (April 2011), published electronically ahead of print.
- Hahn, G.; Khan, H.; Baldanti, F.; Koszinowski, U.H.; Revello, M.G.; Gerna, G. (2002) The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. *Journal of Virology*, Vol.76, No.18, pp. 9551-9555

- Hahn, G.; Rose, D.; Wagner, M.; Rhiel, S.; McVoy, M.A. (2003). Cloning of the genomes of human cytomegalovirus strains Toledo, Towne varRIT3, and Towne long as BACs and site-directed mutagenesis using a PCR-based technique. *Virology*, Vol.307, No.1, pp. 164-177
- Hansen, K.; Napier, I.; Koen, M.; Bradford, S.; Messerle, M.; Bell, E.; Seshadri, L.; Stokes, H.W.; Birch, D.; Whalley, J.M. (2006). In vitro transposon mutagenesis of an equine herpesvirus 1 genome cloned as a bacterial artificial chromosome. *Archives of Virology*, Vol.151, No.12, pp. 2389-2405
- Hansen, S.G.; Powers, C.J.; Richards, R.; Ventura, A.B.; Ford, J.C.; Siess, D.; Axthelm, M.K.; Nelson, J.A.; Jarvis, M.A.; Picker, L.J.; Früh, K. (2010). Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. *Science*, Vol.328, No.5974, pp. 102-106
- Hettich, E.; Janz, A.; Zeidler, R.; Pich, D.; Hellebrand, E.; Weissflog, B.; Moosmann, A.; Hammerschmidt, W. (2006). Genetic design of an optimized packaging cell line for gene vectors transducing human B cells. *Gene Therapy*, Vol.13, No.10, pp. 844-856
- Hobom, U.; Brune, W.; Messerle, M.; Hahn, G.; Koszinowski, U.H. (2000). Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. *Journal of Virology*, Vol.74, No.17, pp. 7720-7729
- Horsburgh, B.C.; Hubinette, M.M.; Qiang, D.; MacDonald, M.L.; Tufaro, F. (1999a). Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes. *Gene Therapy*, Vol.6, No.5, pp. 922-930
- Horsburgh, B.C.; Hubinette, M.M.; Tufaro, F. (1999b). Genetic manipulation of herpes simplex virus using bacterial artificial chromosomes. *Methods of Enzymology*, Vol.306, pp. 337-352
- Ioannou, P.A.; Amemiya, C.T.; Garnes, J.; Kroisel, P.M.; Shizuya, H.; Chen, C.; Batzer, M.A.; de Jong, P.J. (1994). A new bacteriophage P1-derived vector for the propagation of large human DNA fragments. *Nature Genetics*, Vol.6, No.1, pp. 84-89
- Jamsai, D.; Orford, M.; Nefedov, M.; Fucharoen, S.; Williamson, R.; Ioannou, P.A. (2003). Targeted modification of a human beta-globin locus BAC clone using GET recombination and an I-SceI counterselection cassette. *Genomics*, Vol. 82, No.1, pp. 68-77
- Kanda, T.; Yajima, M.; Ahsan, N.; Tanaka, M.; Takada K. (2004). Production of high-titer Epstein-Barr virus recombinants derived from Akata cells by using a bacterial artificial chromosome system. *Journal of Virology*, Vol.78, No.13, pp. 7004-7015
- Karu, A.E.; Sakaki, Y.; Echols, H.; Linn, S. (1975). The gamma protein specified by bacteriophage gamma. Structure and inhibitory activity for the recBC enzyme of Escherichia coli. *Journal of Biological Chemistry*, Vol.250, No.18, pp. 7377-7387
- Kemble, G.; Duke, G.; Winter, R.; Spaete, R. (1996). Defined large-scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. *Journal of Virology*, Vol.70, No.3, pp. 2044-2048
- Kim, U.J.; Shizuya, H.; de Jong, P.J.; Birren, B.; Simon, M.I. (1992). Stable propagation of cosmid sized human DNA inserts in an F factor based vector. *Nucleic Acids Research*, Vol.20, No.5, pp. 1083-1085
- Kmiec, E.; Holloman, W.K. (1981). Beta protein of bacteriophage lambda promotes renaturation of DNA. *Journal of Biological Chemistry*, Vol.256, No.24, pp. 12636-12639

- Kopp, M.; Granzow, H.; Fuchs, W.; Klupp, B.; Mettenleiter T.C. (2004). Simultaneous deletion of pseudorabies virus tegument protein UL11 and glycoprotein M severely impairs secondary envelopment. *Journal of Virology*, Vol.78, No.6, pp. 3024-3034
- Kuroda, T.; Martuza, R.L.; Todo, T.; Rabkin, S.D. (2006). Flipflop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. *BMC Biotechnology*, Vol.6, article No.40
- Lee, E.C.; Yu, D.; Martinez, D.V.; Tessarollo, L.; Swing, D.A.; Court, D.L.; Jenkins, N.A.; Copeland, N.G. (2001). A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. *Genomics*, Vol.73, No.1, pp. 56-65
- Leege, T.; Fuchs, W.; Granzow, H.; Kopp, M.; Klupp, B.G.; Mettenleiter, T.C. (2009). Effects of simultaneous deletion of pUL11 and glycoprotein M on virion maturation of herpes simplex virus type 1. *Journal of Virology*, Vol.83, No.2, pp. 896-907
- Lilja, A.E.; Chang, W.L.; Barry, P.A.; Becerra, S.P.; Shenk, T.E. (2008). Functional genetic analysis of rhesus cytomegalovirus: Rh01 is an epithelial cell tropism factor. *Journal of Virology*, Vol.82, No.5, pp. 2170-2181
- Little, J.W. (1967). An exonuclease induced by bacteriophage lambda. II. Nature of the enzymatic reaction. *Journal of Biological Chemistry*, Vol.242, No.4, pp. 679-686
- Lu, F.; Stedman, W.; Yousef, M.; Renne, R.; Lieberman, P.M. (2010). Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. *Journal of Virology*, Vol.84, No.6, pp. 2697-2706
- Lukac, D.M.; Garibyan, L.; Kirshner, J.R.; Palmeri, D.; Ganem, D. (2001). DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional activation of two viral delayed early promoters. *Journal of Virology*, Vol.75, No.15, pp. 6786-6799
- Luna, R. E.; Zhou, F.; Baghian, A.; Chouljenko, V.; Forghani, B.; Gao, S.J.; Kousoulas, K.G. (2004). Kaposi's sarcoma-associated herpesvirus glycoprotein K8.1 is dispensable for virus entry. *Journal of Virology*, Vol.78, No.12, pp. 6389-6398
- Mahony, T.J.; McCarthy, F.M.; Gravel, J.L.; West, L.; Young, P.L. (2002). Construction and manipulation of an infectious clone of the bovine herpesvirus 1 genome maintained as a bacterial artificial chromosome. *Journal of Virology*, Vol.76, No.13, pp. 6660-6668
- Majerciak, V.; Pripuzova, N.; McCoy, J.P.; Gao, S.J.; Zheng, Z.M. (2007). Targeted disruption of Kaposi's sarcoma-associated herpesvirus ORF57 in the viral genome is detrimenal for the expression of ORF59, K8α, and K8.1 and the production of infectious virus. *Journal of Virology*, Vol.81, No.3, pp. 1062-1071
- Manning, W.C.; Mocarski, E.S. (1988). Insertional mutagenesis of the murine cytomegalovirus genome: one prominent alpha gene (ie2) is dispensable for growth. *Virology*, Vol.167, No.2, 477-484.
- Marchini, A.; Liu, H.; Zhu, H. (2001) Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. *Journal of Virology*, Vol.75, No.4, pp. 1870-1878
- Marconi, P.; Argnani, R.; Epstein, A.L.; Manservigi, R. (2009). HSV as a vector in vaccine development and gene therapy. *Advances in Experimental Medicine and Biology*, Vol. 655, pp. 118-144

- McGregor, A.; Schleiss, M.R. (2001a). Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. *Molecular Genetics and Metabolism*, Vol.72, No.1, pp. 15-26
- McGregor, A.; Schleiss M.R. (2001b). Recent advances in herpesvirus genetics using bacterial artificial chromosomes. *Molecular Genetics and Metabolism*, Vol.72, No.1, pp. 8-14
- Meisinger-Henschel, C.; Späth, M.; Lukassen, S.; Wolferstätter, M.; Kachelriess, H.; Baur, K.; Dirmeier, U.; Wagner, M.; Chaplin, P.; Suter, M.; Hausmann, J. (2011) Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. Journal of Virology, Vol.84, No.19, pp. 9907-9919
- Menard, C.; Wagner, M.; Ruzsics, Z.; Holak, K.; Brune, W.; Campbell, A.E.; Koszinowski, U.H. (2003). Role of murine cytomegalovirus US22 gene family members in replication in macrophages. *Journal of Virology*, Vol.77, No.10, pp. 5557-5570
- Meseda, C.A.; Schmeisser, F.; Pedersen, R.; Woerner, A.; Weir, J.P. (2004). DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome. *Virology*, Vol.318, No.1, pp. 420-428
- Messerle, M.; Crnkovic, I.; Hammerschmidt, W.; Ziegler, H.; Koszinowski, U.H. (1997). Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.94, No.26, pp. 14759-14763
- Mocarski, E.S.; Post, L.E.; Roizman, B. (1980). Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions. *Cell*, Vol.22, No.1, pp. 243-255
- Muniyappa, K.; Radding, C.M. (1986). The homologous recombination system of phage lambda. Pairing activities of beta protein. *Journal of Biological Chemistry*, Vol.261, No.16, pp. 7472-7478
- Murphy, E.; Yu, D.; Grimwood, J.; Schmutz, J.; Dickson, M.; Jarvis, M.A.; Hahn, G.; Nelson, J.A.; Myers, R.M.; Shenk, T.E. (2003) Coding potential of laboratory and clinical strains of human cytomegalovirus. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.100, No.25, pp. 14976-14981
- Murphy, K.C. (1991). Lambda Gam protein inhibits the helicase and chi-stimulated recombination activities of Escherichia coli RecBCD enzyme. *Journal of Bacteriology*, Vol.173, No.18, pp. 5808-5821
- Murphy, K.C. (1998). Use of bacteriophage lambda recombination functions to promote gene replacement in Escherichia coli. *Journal of Bacteriology*, Vol.180, No.8, pp. 2063-2071
- Murphy, K.C. (2007). The lambda Gam protein inhibits RecBCD binding to dsDNA ends. *Journal of Molecular Biology*, Vol.371, No.1, pp. 19-24
- Muyrers, J.P.; Zhang, Y.; Benes, V.; Testa, G.; Rientjes, J.M.; Stewart, A.F. (2004). ET recombination: DNA engineering using homologous recombination in E. coli. *Methods in Molecular Biology*, Vol.256, pp. 107-121
- Muyrers, J.P.; Zhang, Y.; Stewart, A.F. (2001). Techniques: Recombinogenic engineering new options for cloning and manipulating DNA. *Trends in Biochemical Sciences*, Vol.26, No.5, pp. 325-331
- Muyrers, J. P.; Zhang, Y.; Testa, G.; Stewart, A. F. (1999). Rapid modification of bacterial artificial chromosomes by ET-recombination. *Nucleic Acids Research*, Vol.27, No.6, 1555-1557

- Nagaike, K.; Mori, Y.; Gomi, Y.; Yoshii, H.; Takahashi, M.; Wagner, M.; Koszinowski, U.; Yamanishi, K. (2004). Cloning of the varicella zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. *Vaccine*, Vol.22, No.29-30, pp. 4069-4074
- Nagel, C.H.; Döhner, K.; Fathollahy, M.; Strive, T.; Borst, E.M.; Messerle, M.; Sodeik, B. (2008) Nuclear egress and envelopment of herpes simplex virus capsids analyzed with dual-color fluorescence HSV1(17+). Journal of Virology, Vol.82, No.6, pp. 3109-3124
- Narayanan, K.; Williamson, R.; Zhang, Y.; Stewart, A.F.; Ioannou, P.A. (1999). Efficient and precise engineering of a 200 kb beta-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system. *Gene Therapy*, Vol.6, No.3, pp. 442-447.
- O'Hara, M.; Rixon, F.J.; Stow, N.D.; Murray, J.; Murphy, M.; Preston, V.G. (2010). Mutational analysis of the herpes simplex virus type 1 UL25 DNA packaging protein reveals regions that are important after the viral DNA has been packaged. *Journal of Virology*, Vol.84, No.9, pp. 4252-4263
- Oppenheim, A.B.; Rattray, A.J.; Bubunenko, M.; Thomason, L.C.; Court, D.L. (2004). In vivo recombineering of bacteriophage lambda by PCR fragments and single-strand oligonucleotides. *Virology*, Vol.319, No.2, pp. 185-189
- Pavlova, I.V.; Virgin IV, H.W.; Speck, S.H. (2003). Disruption of gammaherpesvirus 68 gene 50 demonstrates that Rta is essential for virus replication. *Journal of Virology*, Vol.77, No.10, pp. 5731-5739
- Petherbridge, L.; Howes, K.; Baigent, S. J.; Sacco, M.A.; Evans, S.; Osterrieder, N.; Nair, V. (2003). Replication-competent bacterial artificial chromosomes of Marek's disease virus: novel tools for generation of molecularly defined herpesvirus vaccines. *Journal of Virology*, Vol.77, No.16, pp. 8712-8718
- Post, L.E.; Roizman, B. (1981). A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. *Cell*, Vol.25, No.1, pp. 227-232
- Ramsay, M. (1994). Yeast artificial chromosome cloning. Molecular Biotechnology, Vol.1, No.2, pp. 181-201.
- Redwood, A.J.; Messerle, M.; Harvey, N.L.; Hardy, C.M.; Koszinowski, U.H.; Lawson, M.A.; Shellam, G.R. (2005). Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. *Journal of Virology*, Vol.79, No.5, pp. 2998-3008
- Richter, M.; Schudel, L.; Tobler, K.; Matheis, F.; Vögtlin, A.; Vanderplasschen, A.; Costes, B.; Spiess, B.; Ackermann, M. (2009). Clinical, virological, and immunological parameters associated with superinfection of latently with FeHV-1 infected cats. *Veterinary Microbiology*, Vol.138, No.3-4, pp. 205-216
- Roberts, A.P.; Abaitua, F.; O'Hare, P.; McNab, D.; Rixon, F.J.; Pasdeloup, D. (2009). Differing roles of inner tegument proteins pUL36 and pUL37 during entry of herpes simplex virus type. *Journal of Virology*, Vol.83, No.1, pp. 105-116
- Robinson, K.E.; Meers, J.; Gravel, J.L.; McCarthy, F.M.; Mahony, T.J. (2008). The essential and non-essential genes of bovine herpesvirus 1. *Journal of General Virology*, Vol.89, No.11, pp. 2851-2863
- Rosas, C.T.; König, P.; Beer, M.; Dubovi, E.J.; Tischer, B.K.; Osterrieder, N. (2007a). Evaluation of the vaccine potential of an equine herpesvirus type 1 vector


- expressing bovine viral diarrhea virus structural proteins. *Journal of General Virology*, Vol.88, No.3, pp. 748-757
- Rosas, C.T.; Paessler, S.; Ni, H.; Osterrieder, N. (2008). Protection of mice by equine herpesvirus type 1-based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies. *American Journal of Tropical Medicine and Hygiene*, Vol.78, No.1, pp. 83-92
- Rosas, C.T.; Tischer, B.K.; Perkins, G.A.; Wagner, B.; Goodman, L.B.; Osterrieder, N. (2007b). Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV). *Virus Research*, Vol.125, No.1, pp. 69-78
- Roth, S.J.; Höper, D.; Beer, M.; Feineis, S.; Tischer, B.K.; Osterrieder, N. (2011) Recovery of infectious virus from full-length cowpox virus (CPXV) DNA cloned as a bacterial artificial chromosome (BAC). *Veterinary Research*, Vol.42, No.1, 3
- Rudolph, J.; O'Callaghan, D.; Osterrieder, N. (2002). Cloning of the genomes of equine herpesvirus type 1 (EHV-1) strains KyA and racL11 as bacterial artificial chromosomes (BAC). *Journal of Veterinary Medicine B*, Vol.49, No.1, pp. 31-36
- Rudolph, J.; Osterrieder, N. (2002). Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. *Virology*, Vol.293, No.2, pp. 356-367
- Rue, C. A.; Jarvis, M. A.; Knoche, A. J.; Meyers, H.L.; DeFilippis, V.R.; Hansen, S.G.; Wagner, M.; Früh, K.; Anders, D.G.; Wong, S.W.; Barry, P.A.; Nelson, J.A. (2004). A cyclooxygenase-2 homologue encoded by rhesus cytomegalovirus is a determinant for endothelial cell tropism. *Journal of Virology*, Vol.78, No.22, pp. 12529-12536
- Saeki, Y.; Ichikawa, T.; Saeki, A.; Chiocca, E.A.; Tobler, K.; Ackermann, M.; Breakefield, X.O.; Fraefel, C. (1998). Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. *Human Gene Therapy*, Vol.9, No.18, pp. 2787-2794
- Sawitzke, J.A.; Thomason, L.C.; Costantino, N.; Bubunenko, M.; Datta, S.; Court, D.L. (2007). Recombineering: in vivo genetic engineering in E. coli, S. enterica, and beyond. *Methods in Enzymology*, Vol.421, pp. 171-199
- Schaffer, P.A. (1975). Temperature-sensitive mutants of herpesviruses. *Current Topics in Microbiology and Immunology*, Vol.70, pp. 51-100
- Schalkwyk, L.C.; Francis, F.; Lehrach, H. (1995). Techniques in mammalian genome mapping. *Current Opinion in Biotechnology*, Vol.6, No.1, pp. 37-43
- Schleiss, M.R. (2008). Comparison of vaccine strategies against congenital CMV infection in the guinea pig model. *Journal of Clinical Virology*, Vol.41, No.3, pp. 224-230
- Schleiss, M.R.; Stroup, G.; Pogorzelski, K.; McGregor, A. (2006). Protection against congenital cytomegalovirus (CMV) disease, conferred by a replication-disabled, bacterial artificial chromosome (BAC)-based DNA vaccine. *Vaccine*, Vol.24, No.37–39, pp. 6175-6186
- Schnee, M.; Ruzsics, Z.; Bubeck, A.; Koszinowski, U.H. (2006). Common and specific properties of herpesvirus UL34/UL31 protein family members revealed by protein complementation assay. *Journal of Virology*, Vol.80, No.23, pp. 11658-11666
- Schumacher, D.; Tischer, B. K.; Fuchs, W.; Osterrieder, N. (2000). Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative MDV-1 mutant. *Journal of Virology*, Vol.74, No.23, pp. 11088-11098

- Sharan, S.K.; Thomason, L.C.; Kuznetsov, S.G.; Court, D.L. (2009). Recombineering: a homologous recombination-based method of genetic engineering. *Nature Protocols*, Vol.4, pp. 206-223.
- Shizuya, H.; Birren, B.; Kim, U.J.; Mancino, V.; Slepak, T.; Tachiiri, Y.; Simon, M. (1992). Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.89, No.18, pp. 8794-8797
- Sinzger, C.; Hahn, G.; Digel, M.; Katona, R.; Sampaio, K.L.; Messerle, M.; Hengel, H.; Koszinowski, U.; Brune, W.; Adler, B. (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. *Journal of General Virology*, Vol.89, No.2, pp. 359-368
- Smiley, J.R. (1980). Construction in vitro and rescue of a thymidine kinase-deficient deletion mutation of herpes simplex virus. *Nature*, Vol. 285, No.5763, pp. 333-335
- Smith, G.A.; Enquist, L.W. (1999). Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. *Journal of Virology*, Vol.73, No.8, pp. 6405-6414
- Smith, G.A.; Enquist, L.W. (2000). A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.97, No.9, pp. 4873-4878
- Song, M.J.; Hwang, S.; Wong, W.H.; Wu, T.T.; Lee, S.; Liao, H.I.; Sun, R. (2005). Identification of viral genes essential for replication of murine γ-herpesvirus 68 using signature-tagged mutagenesis. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.102, No.10, pp. 3805-3810
- Spaderna, S.; Kropff, B.; Ködel, Y.; Shen, S.; Coley, S.; Lu, S.; Britt, W.; Mach, M. (2005). Deletion of gpUL132, a structural component of human cytomegalovirus, results in impaired virus replication in fibroblasts. *Journal of Virology*, Vol.79, No.18, pp. 11837-11847
- Spaete, R.R.; Mocarski, E.S. (1987). Insertion and deletion mutagenesis of the human cytomegalovirus genome. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 84, No.20, pp. 7213-7217
- Sparwasser, T.; Eberl, G. (2007). BAC to immunology bacterial artificial chromosome-mediated transgenesis for targeting of immune cells. *Immunology*, Vol.121, No.3, pp. 308-313
- Stavropoulos, T.A.; Strathdee, C.A. (1998). An enhanced packaging system for helperdependent herpes simplex virus vectors. *Journal of Virology*, Vol.72, No.9, pp. 7137-7143
- St. Jean, J.R.; Desforges, M.; Almazan, F.; Jacomy, H.; Enjuanes, L.; Talbot, P.J. (2006) Recovery of a neurovirulent human coronavirus OC43 from an infectious cDNA clone. *Journal of Virology*, Vol.80, No.7, pp. 3670-3674
- Strive, T.; Hardy, C.M.; French, N.; Wright, J.D.; Nagaraja, N.; Reubel, G.H. (2006). Development of canine herpesvirus based antifertility vaccines for foxes using bacterial artificial chromosomes. *Vaccine*, Vol. 24, No.7, pp. 980-988
- Strive, T.; Hardy, C.M.; Wright, J.; Reubel, G.H. (2007). A virus vector based on canine herpesvirus for vaccine applications in canids. *Veterinary Microbiology*, Vol. 119, No.2-4, pp. 173-183
- Suter, M.; Lew, A.M.; Grob, P.; Adema, G.J.; Ackermann, M.; Shortman, K.; Fraefel, C. (1999). BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial

- chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.96, No.22, pp. 12697-12702
- Tai, S.H.; Niikura, M.; Cheng, H.H.; Kruger, J.M.; Wise, A.G.; Maes, R.K. (2010). Complete genomic sequence and an infectious BAC clone of feline herpesvirus-1 (FHV-1). *Virology*, Vol.401, No.2, pp. 215-227
- Tanaka, M.; Kagawa, H.; Yamanashi, Y.; Sata, T.; Kawaguchi, Y. (2003). Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. *Journal of Virology*, Vol.77, No.2, 1382-1391.
- Terada, K.; Wakimoto, H.; Tyminski, E.; Chiocca, E.A.; Saeki, Y. (2006). Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. *Gene Therapy*, Vol.13, No.8, pp. 705-714
- Thomason, L.; Court, D.L.; Bubunenko, M.; Costantino, N.; Wilson, H.; Datta, S.; Oppenheim, A. (2007). Recombineering: genetic engineering in bacteria using homologous recombination. *Current Protocols in Molecular Biology*, Chapter 1, Unit 1.16.
- Tischer, B.K.; Kaufer, B.B.; Sommer, M.; Wussow, F.; Arvin, A.M.; Osterrieder, N. (2007). A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. *Journal of Virology*, Vol.81, No.23, 13200-13208
- Tischer, B.K.; Smith, G.; Osterrieder, N. (2010a). En passant Mutagenesis A two step markerless Red recombination system. In: Braman, J., In Vitro Mutagenesis Protocols. Humana Press Inc., Tatowa, pp. 221-230.
- Tischer, B.K.; Smith, G.A.; Osterrieder, N. (2010b). En passant mutagenesis: a two step markerless red recombination system. *Methods in Molecular Biology*, Vol.634, pp. 421-430
- Tischer, B.K.; von Einem, J.; Kaufer, B.; Osterrieder, N. (2006). Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. *BioTechniques*, Vol.40, No.2, pp. 191-197
- Tomkinson, B.; Robertson, E.; Yalamanchili, R.; Longnecker, R.; Kieff, E. (1993). Epstein-Barr virus recombinants from overlapping cosmid fragments. *Journal of Virology*, Vol.67, No.12, pp. 7298-7306
- Tong, L.; Stow, N.D. (2010). Analysis of herpes simplex virus type 1 DNA packaging signal mutations in the context of the viral genome. *Journal of Virology*, Vol.84, No.1, pp. 321-329
- Toptan, T; Ensser, A.; Fickenscher, H. (2010) Rhadinovirus vector-derived human telomerase reverse transcriptase expression in primary T cells. *Gene Therapy*, Vol.17, No.5, pp. 653-661
- Trapp, S.; Osterrieder, N.; Keil, G.M.; Beer, M. (2003). Mutagenesis of a bovine herpesvirus type 1 genome cloned as an infectious bacterial artificial chromosome: analysis of glycoprotein E and G double deletion mutants. *Journal of General Virology*, Vol.84, No.2, pp. 301-306

- van Zijl, M.; Quint, W.; Briaire, J.; de Rover, T.; Gielkens, A.; Berns, A. (1988). Regeneration of herpesviruses from molecularly cloned subgenomic fragments. *Journal of Virology*, Vol.62, No.6, 2191-2195
- Wagner, M.; Jonjic, S.; Koszinowski, U.H.; Messerle, M. (1999). Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. *Journal of Virology*, Vol.73, No.8, pp. 7056-7060
- Wagner, M.; Koszinowski, U.H. (2004). Mutagenesis of viral BACs with linear PCR fragments (ET recombination). *Methods in Molecular Biology*, Vol.256, pp. 257-268
- Wagner, M.; Ruzsics, Z.; Koszinowski, U.H. (2002). Herpesvirus genetics has come of age. *Trends in Microbiology*, Vol.10, No.7, pp. 318-324
- Warden, C.; Tang, Q.; Zhu, H. (2011) Herpesvirus BACs: Past, present, and future. *Journal of Biomedicine and Biotechnology* Vol. 2011, Article ID 124595
- Warming, S.; Costantino, N.; Court, D.L.; Jenkins, N.A.; Copeland, N.G. (2005). Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Research*, Vol.33, No.4, article No.e36
- White, R.E.; Calderwood, M.A.; Whitehouse, A. (2003). Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence. *Journal of General Virology*, Vol.84, No.12, pp. 3393-3403
- White, R.E.; Carline, L.; Allday, M.J. (2007). Mutagenesis of the herpesvirus saimiri terminal repeat region reveals important elements for virus production. *Journal of Virology*, Vol.81, No.12, pp. 6765-6770
- Wussow, F.; Fickenscher, H.; Tischer, B.K. (2009). Red-mediated transposition and final reease of the mini-F vector of a cloned infectious herpesvirus genome. PLoS ONE, Vol.4, No.12, pp. 1-9, e8178
- Xu, Y.; AuCoin, D.P.; Rodriguez Huete, A.; Cei, S.A.; Hanson, L.J.; Pari, G.S. (2005). A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. *Journal of Virology*, Vol.79, No.6, pp. 3479-3487
- Xu, Y.; Rodriguez-Huete, A.; Pari, G.S. (2006). Evaluation of the lytic origins of replication of Kaposi's sarcoma-associated virus/human herpesvirus 8 in the context of the viral genome. *Journal of Virology*, Vol.80, No.19, pp. 9905-9909
- Yakushko, Y.; Hackmann, C.; Günther, T.; Rückert, J.; Henke, M.; Koste, L.; Alkharsah, K.; Bohne, J.; Grundhoff, A.; Schulz, T.F.; Henke-Gendo, C. (2011). Kaposi's sarcoma-associated herpesvirus bacterial artificial chromosome contains a duplication of a long unique region fragment within the terminal repeat region. *Journal of Virology* (February 2011), published electronically ahead of print.
- Yang, X.W.; Gong, S. (2005). An overview on the generation of BAC transgenic mice for neuroscience research. *Current Protocols in Neuroscience*, chapter 5.
- Yao, H.; Osterrieder, N.; O'Callaghan, D.J. (2003). Generation and characterization of an EICP0 null mutant of equine herpesvirus 1. *Virus Research*, Vol.98, No.2, pp. 163-172
- Yoshii, H.; Somboonthum, P.; Takahashi, M.; Yamanishi, K.; Mori, Y. (2007). Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus. *Vaccine*, Vol.25, No.27, 5006-5012
- Yu, D.; Ellis, H.M.; Lee, E.C.; Jenkins, N.A.; Copeland, N.G.; Court D.L. (2000). An efficient recombination system for chromosome engineering in Escherichia coli. *Proceedings*

- of the National Academy of Sciences of the United States of America, Vol.97, No.11, 5978-5983
- Yu, D.; Silva, M.C.; Shenk, T. (2003). Functional map of human cytomegalovirus AD169 defined by global mutational analysis. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.100, No.21, pp. 12396-12401
- Yu, D.; Smith, G.A.; Enquist, L.W.; Shenk T. (2002). Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. *Journal of Virology*, Vol.76, No.5, pp. 2316-2328
- Zhang, Y.; Buchholz, F.; Muyrers, J.P.; Stewart, A.F. (1998). A new logic for DNA engineering using recombination in Escherichia coli. *Nature Genetics*, Vol.20, No.2, 123-128
- Zhang, Z.; Rowe, J.; Wang, W.; Sommer, M.; Arvin, A.; Moffat, J.; Zhu, H. (2007). Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. *Journal of Virology*, Vol.81, No.17, pp. 9024-9033
- Zhang, Z.; Huang, Y.; Zhu, H. (2008). A highly efficient protocol of generating and analyzing VZV ORF deletion mutants based on a newly developed luciferase VZV BAC system. *Journal of Virological Methods*, Vol.148, No.1-2, pp. 197-204
- Zhang, Z.; Selariu, A.; Warden, C.; Huang, G.; Huang, Y.; Zaccheus, O.; Cheng, T.; Xia, N.; Zhu, H. (2010). Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. *PLoS Pathogens*, Vol.6, No. e1000971
- Zhao, Y.; Petherbridge, L.; Smith, L. P.; Baigent, S.; Nair, V. (2008). Self-excision of the BAC sequences from the recombinant Marek's disease virus genome increases replication and pathogenicity. *Virology Journal*, Vol.5, article No.19
- Zhou, F.; Li, Q.; Wong, S.W.; Gao, S.J. (2010). Autoexcision of bacterial artificial chromosome facilitated by terminal repeat-mediated homologous recombination: a novel approach for generating traceless genetic mutants of herpesviruses. *Journal of Virology*, Vol.84, No.6, pp. 2871-2880
- Zhou, F.C.; Zhang, Y.J.; Deng, J.H.; Wang, X.P.; Pan, H.Y.; Hettler, E.; Gao, S.J. (2002). Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. *Journal of Virology*, Vol.76, No.12, pp. 6185-6196



DNA Replication-Current Advances

Edited by Dr Herve Seligmann

ISBN 978-953-307-593-8
Hard cover, 694 pages
Publisher InTech
Published online 01, August, 2011
Published in print edition August, 2011

The study of DNA advanced human knowledge in a way comparable to the major theories in physics, surpassed only by discoveries such as fire or the number zero. However, it also created conceptual shortcuts, beliefs and misunderstandings that obscure the natural phenomena, hindering its better understanding. The deep conviction that no human knowledge is perfect, but only perfectible, should function as a fair safeguard against scientific dogmatism and enable open discussion. With this aim, this book will offer to its readers 30 chapters on current trends in the field of DNA replication. As several contributions in this book show, the study of DNA will continue for a while to be a leading front of scientific activities.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Felix Wussow, Tanja Spieckermann, Anne Brunnemann, Linda Hüske, Tuna Toptan and Helmut Fickenscher (2011). Bacterial Genetics of Large Mammalian DNA Viruses: Bacterial Artificial Chromosomes as a Prerequisite for Efficiently Studying Viral DNA Replication and Functions, DNA Replication-Current Advances, Dr Herve Seligmann (Ed.), ISBN: 978-953-307-593-8, InTech, Available from: http://www.intechopen.com/books/dna-replication-current-advances/bacterial-genetics-of-large-mammalian-

http://www.intechopen.com/books/dna-replication-current-advances/bacterial-genetics-of-large-mammalian-dna-viruses-bacterial-artificial-chromosomes-as-a-prerequisite



InTech Europe

University Campus STeP Ri Slavka Krautzeka 83/A 51000 Rijeka, Croatia Phone: +385 (51) 770 447

Fax: +385 (51) 686 166 www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai No.65, Yan An Road (West), Shanghai, 200040, China 中国上海市延安西路65号上海国际贵都大饭店办公楼405单元

Phone: +86-21-62489820 Fax: +86-21-62489821 © 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the <u>Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License</u>, which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.



